Original Article
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
N Engl J Med 2004; 350:1516-1525April 8, 2004
- Abstract
Background
Treatment of secondary hyperparathyroidism with vitamin D and calcium in patients receiving dialysis is often complicated by hypercalcemia and hyperphosphatemia, which may contribute to cardiovascular disease and adverse clinical outcomes. Calcimimetics target the calcium-sensing receptor and lower parathyroid hormone levels without increasing calcium and phosphorus levels. We report the results of two identical randomized, double-blind, placebo-controlled trials evaluating the safety and effectiveness of the calcimimetic agent cinacalcet hydrochloride.
Methods
Patients who were receiving hemodialysis and who had inadequately controlled secondary hyperparathyroidism despite standard treatment were randomly assigned to receive cinacalcet (371 patients) or placebo (370 patients) for 26 weeks. Once-daily doses were increased from 30 mg to 180 mg to achieve intact parathyroid hormone levels of 250 pg per milliliter or less. The primary end point was the percentage of patients with values in this range during a 14-week efficacy-assessment phase.
Results
Forty-three percent of the cinacalcet group reached the primary end point, as compared with 5 percent of the placebo group (P<0.001). Overall, mean parathyroid hormone values decreased 43 percent in those receiving cinacalcet but increased 9 percent in the placebo group (P<0.001). The serum calcium–phosphorus product declined by 15 percent in the cinacalcet group and remained unchanged in the placebo group (P<0.001). Cinacalcet effectively reduced parathyroid hormone levels independently of disease severity or changes in vitamin D sterol dose.
Conclusions
Cinacalcet lowers parathyroid hormone levels and improves calcium–phosphorus homeostasis in patients receiving hemodialysis who have uncontrolled secondary hyperparathyroidism.
Media in This Article
Figure 1
Percentage of Randomized Patients Who Had a Parathyroid Hormone Level of 250 pg per Milliliter or Less or a Reduction in the Parathyroid Hormone Level of 30 Percent or More (Panel A), Percentage of Randomized Patients with a Parathyroid Hormone Level of 250 pg per Milliliter or Less at Each Time Point (Panel B), and Percentage of Patients with a Reduction from Base Line in the Parathyroid Hormone Level of at Least 30 Percent during the Efficacy-Assessment Phase, Stratified According to the Severity of Secondary Hyperparathyroidism (Panel C).Figure 2
Mean (±SE) Plasma Parathyroid Hormone Level (Panel A), Percent Change in the Level from Base Line at Each Time Point (Panel B), and Mean (±SE) Plasma Full-Length Parathyroid Hormone Level (Panel C).Article Activity
- Article
Secondary hyperparathyroidism is common in patients with chronic kidney disease, affecting most of those who are receiving hemodialysis.1,2 The disorder is characterized by persistently elevated levels of parathyroid hormone and complicated by important disturbances in mineral metabolism.3
Bone disease is the most widely recognized consequence of secondary hyperparathyroidism.4 Several reports indicate, however, that alterations in calcium and phosphorus metabolism, as a result of either secondary hyperparathyroidism or the therapeutic measures used to manage it, contribute to soft-tissue and vascular calcification, cardiovascular disease, and the risk of death.5-10 Episodes of hypercalcemia and hyperphosphatemia are often aggravated by the use of large doses of calcium as a phosphate-binding agent, particularly in combination with vitamin D sterols, which increase the absorption of calcium and phosphorus.10-13 There is thus considerable interest in identifying therapeutic alternatives that control secondary hyperparathyroidism while limiting these side effects.
The calcium-sensing receptor regulates the secretion of parathyroid hormone.14 Calcimimetic agents increase the sensitivity of the calcium-sensing receptor to extracellular calcium ions,15,16 inhibit the release of parathyroid hormone, and lower parathyroid hormone levels within a few hours after administration.17-19 This mechanism of action differs fundamentally from that of vitamin D sterols, which diminish the transcription of the parathyroid hormone gene and hormone synthesis over a period of many hours or several days.20 Results of previous small clinical trials indicate that the calcimimetic agent cinacalcet hydrochloride not only reduces parathyroid hormone levels but also lowers serum calcium and phosphorus levels in patients with secondary hyperparathyroidism.21-23 We report the combined results of two large phase 3 clinical trials of identical design to determine the safety and effectiveness of cinacalcet for treating secondary hyperparathyroidism in patients undergoing hemodialysis.
Methods
Study Participants
Study candidates were patients in medically stable condition with secondary hyperparathyroidism who were 18 years of age or older and who had been treated with thrice-weekly hemodialysis for at least three months. The primary eligibility criterion was a mean plasma parathyroid hormone level of at least 300 pg per milliliter (31.8 pmol per liter), established by three measurements obtained within a 30-day screening period. Dialysate calcium levels remained unchanged throughout the study.
Exclusion criteria included evidence of cancer, active infection, diseases known to cause hypercalcemia, or a serum calcium level below 8.4 mg per deciliter (2.1 mmol per liter), corrected for albumin.24 Because cinacalcet can inhibit cytochrome P-450 2D6, patients were excluded if they were receiving drugs such as flecainide, thioridazine, and most tricyclic antidepressants, which have a narrow therapeutic index and are metabolized by this enzyme.
The study protocols were reviewed and approved by the institutional review board at each study site, and written informed consent was obtained from each patient before enrollment. The study was designed by Amgen in collaboration with the authors. The complete data set was held at the central data-processing facility at Amgen. Statistical analyses and data interpretation were conducted by Amgen in collaboration primarily with Drs. Block and Goodman. The investigators had unrestricted access to the primary data and were not limited by the sponsor with regard to statements made in the final article. The lead investigators were responsible for writing the article, with editorial assistance from Amgen.
Study Design
Two identical randomized, double-blind, placebo-controlled clinical trials were conducted at 63 sites in North America and 62 sites in Europe and Australia between December 20, 2001, and January 16, 2003. A total of 1270 patients were screened for entry. Of these, 741 satisfied eligibility criteria (410 in North America and 331 in Europe and Australia) and were randomly assigned to receive cinacalcet (371 patients) or placebo (370 patients). Randomization was stratified according to disease severity and base-line values for the calcium–phosphorus product. No more than 20 percent of the study population could have parathyroid hormone levels exceeding 800 pg per milliliter (84.8 pmol per liter).
The treatment phase of both studies lasted 26 weeks and consisted of a 12-week dose-titration phase followed by a 14-week efficacy-assessment phase. The initial dose of cinacalcet (or placebo) was 30 mg given orally once daily. The doses were increased sequentially every three weeks during the dose-titration phase to 60, 90, 120, or 180 mg once daily. Increases in the dose were permitted if parathyroid hormone levels remained above 200 pg per milliliter (21.2 pmol per liter) and serum calcium levels were at least 7.8 mg per deciliter (1.95 mmol per liter). The dose was not increased if symptoms of hypocalcemia developed, if serum calcium levels were less than 7.8 mg per deciliter, or if patients had an adverse event that precluded an increase in the dose. The dose was reduced if parathyroid hormone levels were less than 100 pg per milliliter (10.6 pmol per liter) on three consecutive study visits or if patients reported an adverse event requiring a reduction in the dose. Dose adjustments were permitted at four-week intervals during the efficacy-assessment phase.
Mineral metabolism was managed according to current standards of care with the use of phosphate-binding medications, vitamin D sterols, or both. No restrictions were imposed on the dose or type of phosphate binder. Increases in the dose of vitamin D sterols were permitted if parathyroid hormone levels rose by 50 percent or more from base line, if serum calcium levels were below 8.4 mg per deciliter (2.1 mmol per liter), or if patients had symptoms of hypocalcemia. Doses of vitamin D sterols were reduced if calcium levels were 11.0 mg per deciliter (2.75 mmol per liter) or higher, phosphorus levels were 6.5 mg per deciliter (2.1 mmol per liter) or higher, calcium–phosphorus product values were 70 mg2 per square deciliter (5.6 mmol2 per square liter) or greater, or parathyroid hormone levels were less than 100 pg per milliliter on three consecutive study visits for patients receiving the lowest daily dose of cinacalcet.
Biochemical Determinations
Plasma parathyroid hormone levels and serum calcium and phosphorus levels were measured at each study visit before hemodialysis, approximately 24 hours after the preceding dose but before the next daily dose of study medication. Serum levels of bone-specific alkaline phosphatase were measured at base line and at 26 weeks.
Biochemical measurements were made at three regional reference laboratories (Covance Laboratory Services, Indianapolis; Covance Central Laboratory Services, Geneva; and Sonic Clinical Trials, Sydney, Australia). Parathyroid hormone levels were determined in all patients with the use of a conventional immunometric assay (Allegro PTH, Nichols Institute Diagnostics).25 For patients in the North American trial, measurements were also made with the use of an immunometric assay that detects only the full-length hormone (Bio-Intact PTH, Nichols Institute Diagnostics). Bone-specific alkaline phosphatase levels were determined with the use of the Tandem-R Ostase two-site immunoradiometric assay (Beckman-Coulter).
Study End Points
The primary study end point was the proportion of randomized patients who had a mean parathyroid hormone level of 250 pg per milliliter (26.5 pmol per liter) or less during the efficacy-assessment phase. Secondary end points included the proportion of patients with a reduction from base line of at least 30 percent in mean parathyroid hormone levels and the percent change in the values for parathyroid hormone, calcium, phosphorus, and the calcium–phosphorus product.
Statistical Analysis
Data from the two identical studies were combined for this analysis. Logistic regression confirmed that the country of enrollment had no effect on the likelihood of achieving the primary end point (P=0.82). Base-line laboratory measurements were obtained and patients' characteristics were noted during the screening period. Mean values for parathyroid hormone, calcium, phosphorus, and the calcium–phosphorus product during the efficacy-assessment phase were calculated with the use of all available results from each patient (up to seven values per patient). A single measurement of bone-specific alkaline phosphatase at week 26 was used to assess changes from base line.
Patients who withdrew from the study during the dose-titration phase were considered not to have met either the primary end point or the secondary end point of a reduction in parathyroid hormone levels of at least 30 percent. For patients who did not have any values for the efficacy-assessment phase, the mean of the last two values obtained during the study was used as the average for weeks 13 through 26 for parathyroid hormone, calcium, phosphorus, and the calcium–phosphorus product. The safety analysis included all patients who received at least one dose of study medication.
Results for all laboratory variables except bone-specific alkaline phosphatase are expressed as means ±SD or means ±SE, as indicated. Because bone-specific alkaline phosphatase values were not normally distributed, the results are expressed as medians and interquartile ranges. For categorical variables, the Cochran–Mantel–Haenszel test,26 stratified according to base-line parathyroid hormone levels and calcium–phosphorus product values, was used to examine differences between treatment groups during the efficacy-assessment phase. The generalized Cochran–Mantel–Haenszel test26 was used for continuous variables. No interim analyses were performed.
Cochran–Mantel–Haenszel tests were used to estimate the relative risk of the primary end point in the cinacalcet group, as compared with the placebo group, according to age, sex, race, duration of dialysis, base-line biochemical variables, presence or absence of diabetes, and use (or nonuse) of vitamin D sterols. Logistic regression was used to identify factors that predicted a reduction in parathyroid hormone levels of at least 30 percent. All P values were two-sided, and those less than 0.05 were considered to indicate statistical significance. Statistical calculations were performed with SAS software (version 8.2, SAS Institute).
Results
The base-line demographic characteristics and biochemical results did not differ significantly between groups (Table 1Table 1
Base-Line Demographic Characteristics. and Table 2Table 2
Biochemical Determinations.). Nearly all patients were receiving phosphate-binding agents, and there were no significant differences between groups in the type of agents used. Two thirds of patients were receiving vitamin D sterols at enrollment. Although 9 percent of patients (63 of 741) had never been treated with vitamin D sterols, 20 percent (149 of 741) were not being treated because hypercalcemia, hyperphosphatemia, or both precluded their use.Eighty-two percent of patients who were randomly assigned to cinacalcet (306 of 371) and 88 percent of patients who were randomly assigned to placebo (325 of 370) completed the dose-titration phase; 68 percent and 78 percent, respectively, completed 26 weeks of treatment. Reasons for early discontinuation included adverse events (15 percent of patients receiving cinacalcet and 7 percent of those receiving placebo), withdrawal of consent (4 percent and 3 percent, respectively), kidney transplantation (4 percent in each group), and death (2 percent in each group). None of the deaths were considered to be related to treatment.
Forty-three percent of patients receiving cinacalcet (160 of 371) reached the primary end point — a mean parathyroid hormone level of 250 pg per milliliter or less during the efficacy-assessment phase — as compared with 5 percent of those receiving placebo (19 of 370, P<0.001) (Figure 1AFigure 1
Percentage of Randomized Patients Who Had a Parathyroid Hormone Level of 250 pg per Milliliter or Less or a Reduction in the Parathyroid Hormone Level of 30 Percent or More (Panel A), Percentage of Randomized Patients with a Parathyroid Hormone Level of 250 pg per Milliliter or Less at Each Time Point (Panel B), and Percentage of Patients with a Reduction from Base Line in the Parathyroid Hormone Level of at Least 30 Percent during the Efficacy-Assessment Phase, Stratified According to the Severity of Secondary Hyperparathyroidism (Panel C).). The proportion of patients who reached the primary end point rose throughout the study in the cinacalcet group but remained unchanged in the placebo group (Figure 1B). Mean parathyroid hormone levels decreased by 30 percent or more in 64 percent of patients given cinacalcet (239 of 371), as compared with 11 percent of those given placebo (42 of 370, P<0.001) (Figure 1A). The proportions of patients whose parathyroid hormone levels decreased by at least 30 percent during treatment with cinacalcet did not differ significantly according to base-line values (Figure 1C).Parathyroid hormone levels were significantly lower in patients given cinacalcet than in those receiving placebo (P<0.001) (Figure 2AFigure 2
Mean (±SE) Plasma Parathyroid Hormone Level (Panel A), Percent Change in the Level from Base Line at Each Time Point (Panel B), and Mean (±SE) Plasma Full-Length Parathyroid Hormone Level (Panel C).). During the efficacy-assessment phase, mean parathyroid hormone levels were 43 percent lower than base line in patients receiving cinacalcet but 9 percent higher in those receiving placebo (P<0.001) (Figure 2B and Table 2). Among the 410 patients who had parathyroid hormone levels measured by two different methods (Table 2), results were highly correlated both before (r=0.923) and during treatment (r=0.962 in the cinacalcet group and r=0.949 in the placebo group). Mean levels of full-length parathyroid hormone were reduced by 38 percent in cinacalcet-treated patients but increased by 23 percent in those receiving placebo (P<0.001) (Table 2 and Figure 2C). Median serum values for bone-specific alkaline phosphatase decreased 35 percent in patients given cinacalcet and 4 percent in those given placebo (P<0.001) (Table 2).In stratified analyses, the likelihood of achieving the primary end point was greater among patients given cinacalcet than among those given placebo and was not influenced by sex, race, age, duration of dialysis, base-line biochemical variables, the presence of diabetes, or the use of vitamin D sterols (Figure 3Figure 3
Stratified Analysis of the Likelihood of Achieving a Parathyroid Hormone Level of 250 pg per Milliliter or Less in the Cinacalcet Group as Compared with the Placebo Group.). Multivariate logistic-regression analysis showed that the odds of achieving at least a 30 percent reduction in parathyroid hormone were 15 times as great among patients who received cinacalcet as among patients who received placebo (odds ratio, 15.38; 95 percent confidence interval, 10.31 to 22.95) and nearly 1.7 times as great among whites as among blacks (odds ratio, 1.68; 95 percent confidence interval, 1.12 to 2.54). Blacks were 4.1 times (95 percent confidence interval, 2.6 to 6.6) as likely to have a reduction of at least 30 percent in parathyroid hormone levels during cinacalcet therapy as during placebo administration.Treatment with cinacalcet was associated with moderate reductions in serum calcium and phosphorus levels, averaging 6.8 percent and 8.4 percent, respectively (P<0.001), whereas values were not significantly changed in the placebo group (Table 2). Values for the calcium–phosphorus product decreased by 14.6 percent in the cinacalcet group (P<0.001) but did not change significantly in the placebo group (Figure 4Figure 4
Mean (±SE) Values for the Serum Calcium–Phosphorus Product. and Table 2). Eighty-nine percent of cinacalcet-treated patients who reached the primary end point (143 of 160) had a concurrent reduction in the calcium–phosphorus product.The average doses of phosphate-binding agents and vitamin D sterols did not differ significantly between groups. The proportion of patients who received vitamin D during the study was 82 percent in the cinacalcet group and 78 percent in the placebo group. Cinacalcet reduced parathyroid hormone levels regardless of whether the vitamin D doses were increased, were decreased, or remained unchanged (reductions of 52 percent, 43 percent, and 44 percent, respectively). The percent reductions in the calcium–phosphorus product were greater in the cinacalcet group than in the placebo group, regardless of whether the vitamin D dose was increased, was decreased, or remained unchanged (reductions of 13 percent, 19 percent, and 17 percent, respectively).
At least one adverse event was reported by 91 percent of patients in the cinacalcet group (333 of 365) and 94 percent of patients in the placebo group (346 of 369, P=0.21). Nausea occurred more often in those given cinacalcet than in those given placebo (32 percent vs. 19 percent, P<0.001), as did vomiting (30 percent vs. 16 percent, P<0.001), whereas upper respiratory tract infection occurred more often in those given placebo than in those who received cinacalcet (13 percent vs. 7 percent, P=0.007), as did hypotension (12 percent vs. 6 percent, P=0.014). The frequency of nausea was unrelated to the dose of cinacalcet, whereas vomiting occurred more frequently at higher doses. Gastrointestinal effects among patients treated with cinacalcet were generally mild to moderate in severity and of limited duration. Fewer than 5 percent of patients in the cinacalcet group and less than 1 percent of patients in the placebo group were withdrawn from the study because of either nausea or vomiting.
Serum calcium levels were below 7.5 mg per deciliter (1.9 mmol per liter) on at least two consecutive measurements in 5 percent of patients given cinacalcet and in less than 1 percent of patients given placebo (P<0.001). Episodes were transient, rarely associated with symptoms, and managed by modifying doses of calcium-containing phosphate-binding agents, vitamin D sterols, or both. Overall, the extent of the decreases in the serum calcium level did not differ significantly between patients given cinacalcet alone and those given cinacalcet together with vitamin D sterols. One patient in each group was withdrawn from the study because of hypocalcemia.
Discussion
Our results indicate that cinacalcet effectively reduces parathyroid hormone levels in patients with secondary hyperparathyroidism who are receiving hemodialysis and ameliorates disturbances in serum calcium and phosphorus that have been associated with adverse clinical outcomes. Our patients had been treated with dialysis for an average of six years and had persistently elevated parathyroid hormone levels despite the use of vitamin D sterols and phosphate binders. Nevertheless, parathyroid hormone levels declined rapidly during treatment with cinacalcet, and this response was sustained for the duration of the study. Forty-three percent of cinacalcet-treated patients had a mean parathyroid hormone level of 250 pg per milliliter or less, a value generally considered to reflect adequate control of secondary hyperparathyroidism.27 Over 60 percent of those receiving cinacalcet had a decrease of at least 30 percent in plasma parathyroid hormone levels. The reductions in parathyroid hormone in those given cinacalcet were accompanied by decreases in serum calcium, phosphorus, and bone-specific alkaline phosphatase levels and the calcium–phosphorus product.
In previous studies, parathyroid hormone levels decreased rapidly after the administration of cinacalcet, with maximal responses at two to four hours.21,22 In our study, parathyroid hormone was measured 24 hours after dosing and thus represents a conservative estimate of efficacy.
The use of vitamin D sterols to lower parathyroid hormone levels, particularly in combination with calcium-containing phosphate binders, can cause hypercalcemia and hyperphosphatemia by promoting intestinal absorption of calcium and phosphorus.12,13,28,29 These disturbances often interrupt treatment, leading to inadequate biochemical control and progression of bone disease.28,30 Such derangements are also associated with an increased risk of death, increased arterial stiffness, and calcification of the coronary arteries, aorta, and cardiac valves.6-10 Vitamin D sterols had been withheld from 20 percent of our patients at study entry owing to elevated levels of serum phosphorus, calcium, or both. Thus, the fact that cinacalcet lowers parathyroid hormone levels while reducing serum calcium and phosphorus levels represents a potentially important therapeutic development.
Stratified analysis demonstrated the effectiveness of cinacalcet across a broad range of demographic subgroups and base-line characteristics. Decreases in parathyroid hormone levels during cinacalcet therapy did not differ according to the dose of vitamin D sterols. Although definitive studies are needed to assess the role of cinacalcet as primary therapy, a subgroup of patients receiving cinacalcet as primary treatment appeared to have a response. Because their mechanisms of action differ, cinacalcet and vitamin D may have additive effects that act to lower parathyroid hormone levels, but this possibility will require further study.
Treatment with cinacalcet was generally well tolerated. Episodes of nausea and vomiting occurred more often in cinacalcet-treated patients but were generally mild to moderate in severity and transient. Serum calcium values below the normal range were rarely associated with symptoms of hypocalcemia and were readily managed by means of adjustments in the doses of calcium-containing phosphate binders, vitamin D sterols, or both.
In contrast to earlier trials,21-23 our study included a larger number of patients, higher maximal doses of cinacalcet, demographically diverse subjects, and a longer duration of follow-up. Thus, our approach more closely approximates clinical practice, since the management of secondary hyperparathyroidism spans a wide range of disease severity over extended periods of time. Our study nonetheless has certain limitations. Although parathyroid hormone levels decreased and disturbances in calcium and phosphorus metabolism improved, we did not assess the effect of these changes on bone histologic features, bone mass, arterial and soft-tissue calcification, arterial stiffness, and cardiovascular events in these six-month clinical trials. Longer studies will be required to address these skeletal and cardiovascular issues adequately. Nevertheless, the effectiveness of cinacalcet in lowering parathyroid hormone levels and its favorable effect on biochemical variables that have been associated with adverse clinical outcomes represent noteworthy findings.
By directly targeting the molecular mechanism that regulates the secretion of parathyroid hormone, the calcimimetic agent cinacalcet provides a novel therapeutic approach for controlling secondary hyperparathyroidism in patients with chronic kidney disease. The use of treatment strategies that include cinacalcet may make it possible to achieve the more stringent therapeutic guidelines now recommended for managing secondary hyperparathyroidism.31
Supported by Amgen.
Dr. Block reports having received consulting fees, lecture fees, and a grant from Genzyme and lecture fees and consulting fees from Amgen and Abbott Laboratories. Dr. Martin reports having received grant support and lecture fees from Abbott Laboratories. Dr. Abu-Alfa reports having received consulting and lecture fees from Amgen and Baxter, consulting fees from Ortho Biotech, and a grant from Baxter. Dr. de Francisco reports having received consulting fees from Amgen and lecture fees from Roche, Baxter, and Janssen Cilag. Dr. Cunningham reports having received consulting fees, lecture fees, and a grant from Amgen and consulting fees from Genzyme. Dr. Braun reports having received lecture and consulting fees from Amgen. Dr. Coyne reports having received lecture and consulting fees from Amgen. Dr. Cohen reports having received grant support from Amgen. Dr. Suranyi reports having received consulting and lecture fees from Baxter; lecture fees from Amgen, Janssen Cilag, and Bayer; and consulting fees from Astra. Dr. Messa reports having received lecture fees from Amgen. Dr. Locatelli reports having received consulting and lecture fees from Amgen. Dr. Zani, Dr. Turner, and Mr. Olson are employees of Amgen and report having equity ownership in Amgen. Dr. Drüeke reports having received consulting and lecture fees from Amgen and Genzyme, consulting fees from Roche, and grant support from Genzyme and Freud/Salt Industry. Dr. Moe reports having received consulting fees, lecture fees, and grant support from Amgen and grant support from Abbott and Genzyme. Dr. McCary reports having equity ownership in Amgen. Dr. Goodman reports having received consulting and lecture fees from, as well as having equity ownership in, Amgen.
We are indebted to Drs. Glenn Chertow and Catherine Stehman-Breen for their critical review of the manuscript and to Holly Brenza Zoog for assistance in the preparation of the manuscript.
Source Information
From Denver Nephrologists, Denver (G.A.B.); Saint Louis University, St. Louis (K.J.M.); Hospital Marqués de Valdecilla, Santander, Spain (A.L.M.F.); Amgen, Thousand Oaks, Calif. (S.A.T., L.C.M., V.J.Z., K.A.O.); Long Island College Hospital, Brooklyn, N.Y. (M.M.A.); Liverpool Hospital, Liverpool, NSW, Australia (M.G.S.); Humber River Regional Hospital, Toronto (G.H.); University College London Hospitals, London (J.C.); Yale University School of Medicine, New Haven, Conn. (A.K.A.-A.); Ospedale Civile S. Andrea, La Spezia, Italy (P.M.); Washington University School of Medicine, St. Louis (D.W.C.); Ospedale Manzoni, Lecco, Italy (F.L.); Presbyterian Medical Center, Philadelphia (R.M.C.); Universitaire Ziekenhuis Gasthuisberg, Leuven, Belgium (P.E.); Indiana University School of Medicine, Indianapolis (S.M.M.); Centre Hospitalier Universitaire d'Amiens, Amiens, France (A.F.); Kuratorium für Dialyse, Nuremberg, Germany (J.B.); Necker Hospital, Paris (T.B.D.); and UCLA School of Medicine, Los Angeles (W.G.G.).
Address reprint requests to Dr. Block at Denver Nephrologists, 1601 E. 19th Ave. #4300, Denver, CO 80218, or at gablock@denverneph.net.
Appendix
In addition to the authors, the following investigators participated in the Cinacalcet North American Study: S. Acchiardo (Memphis, Tenn.), M. Anger (Thornton, Colo.), J. Anzalone (Wenatchee, Wash.), J. Arruda (Chicago), M. Belledonne (Rockville, Md.), J. Brennan (Fort Worth, Tex.), D. Bushinski (Rochester, N.Y.), E. Brown (Stamford, Conn.), P. Campbell (Edmonton, Canada), R. Clark (Lafayette, La.), L. Cohen (Cincinnati), C. Corpier (Dallas), R.M. Culpepper (Mobile, Ala.), M. Curzi (Walnut Creek, Calif.), J. Diego (Miami), M. Faber (Detroit), G. Fadda (San Diego, Calif.), A. Fine (Winnipeg, Canada), D. Fischer (Cincinnati), L. Garret, Jr. (Raleigh, N.C.), M. Germain (W. Springfield, Mass.), Y. Jean-Claude (New York), M. Kaplan (Nashville), M. Koren (Jacksonville, Fla.), K.S. Kant (Cincinnati), A. Kshirsagar (Chapel Hill, N.C.), M. Joy (Chapel Hill, N.C.), J. Lewis (Birmingham, Ala.), J. Lindberg (New Orleans), B. Ling (Asheville, N.C.), N.D. Makoff (Los Angeles), N.E. Mansour (Memphis, Tenn.), B. Michael (Philadelphia), S. Mischel (Hammond, Ind.), G. Nassar (Houston), N. Pokroy (Las Vegas), R. Provenzano (Detroit), S.N. Rahman (Houston), R. Raja (Philadelphia), S. Rosansky (Columbia, S.C.), C. Shadur (Des Moines, Iowa), D. Sherrard (Seattle), M. Silver (Cleveland), S. Soroka (Halifax, Canada), D. Spiegel (Denver), S. Sprague (Evanston, Ill.), R. Sreedhara (New Port Richey, Fla.), C. Stehman-Breen (Seattle), J.R. Sterrett (Paterson, N.J.), J. Strom (Boston), K. Tucker (Simi Valley, Calif.), I. Wahba (Portland, Oreg.), D. Wombolt (Norfolk, Va.), S. Zeig (Pembroke Pines, Fla.).
In addition to the authors, the following investigators participated in the Cinacalcet European and Australian Study: A. Albertazzi (Modena, Italy), A. Alvestrand (Huddinge, Sweden), U. Bahner (Würzburg, Germany), J. Barata (Amadora, Portugal), J. Berglund (Danderyd, Sweden), Y. Berland (Marseilles, France), H.S. Brink (Enschede, the Netherlands), G. Cancarini (Brescia, Italy), G. Cannella (Genoa, Italy), F. Caravaca (Badajoz, Spain), J. Chanard (Rheims, France), G. Civati (Milan, Italy), P. Conlon (Dublin, Ireland), H. Deuber (Erlangen, Germany), A. Disney (Woodville, S.A., Australia), A. Ferreira (Vila Franca de Xira, Portugal), R. Fiedler (Halle/Salle, Germany), J. Frazão (Porto, Portugal), H. Geiger (Frankfurt, Germany), P. Gerlag (Veldhoven, the Netherlands), R. Gokal (Manchester, United Kingdom), A. Gomes da Costa (Lisbon, Portugal), M. González (Barcelona, Spain), E. Hagen (Amersfoort, the Netherlands), W. Höerl (Vienna, Austria), H. Holzer (Graz, Austria), B. Hutchison (Nedlands, W.A., Australia), E. Imbasciati (Lodi, Italy), M. Jadoul (Brussels, Belgium), P. Jaeger (Nice, France), D. Johnson (Woolloongabba, Qld., Australia), P. Kerr (Clayton, Vic., Australia), R. Kramar (Wels, Austria), M. Laville (Lyons, France), A. Martín-Malo (Córdoba, Spain), G. Mayer (Innsbruck, Austria), G. Mellotte (Dublin, Ireland), U. Neyer (Feldkirch, Austria), K. Ølgaard (Copenhagen, Denmark), P. Ponce (Corroios, Portugal), H. Reichel (Villingen-Schwenningen, Germany), E. Ritz (Heidelberg, Germany), J. Rodicio (Madrid), H. Saha (Tampere, Finland), G. Stein (Jena, Germany), H.K. Stummvoll (Linz, Austria), C. Tielemans (Brussels, Belgium), V. Torregrosa (Barcelona, Spain), P. Ureña-Torres (Aubervilliers, France), M. Van den Dorpel (Rotterdam, the Netherlands), Y. Vanrenterghem (Leuven, Belgium), R. Walker (Parkville, Vic., Australia), B. Wikström (Uppsala, Sweden), M. Wilkie (Sheffield, United Kingdom).
- References
References
1
Salem MM . Hyperparathyroidism in the hemodialysis population: a survey of 612 patients. Am J Kidney Dis 1997;29:862-865
CrossRef | Web of Science | Medline2
Owda A . Elhwairis H, Narra S, Towery H, Osama S. Secondary hyperparathyroidism in chronic hemodialysis patients: prevalence and race. Ren Fail 2003;25:595-602
CrossRef | Web of Science | Medline3
Slatopolsky E ,Brown A ,Dusso A . Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 1999;73:S14-S19
CrossRef | Medline4
Hruska KA ,Teitelbaum SL . Renal osteodystrophy. N Engl J Med 1995;333:166-174
Full Text | Web of Science | Medline5
Block GA ,Hulbert-Shearon TE ,Levin NW ,Port FK . Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-617
CrossRef | Web of Science | Medline6
Ribeiro S ,Ramos A ,Brandao A , et al. Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant 1998;13:2037-2040
CrossRef | Web of Science | Medline7
Goodman WG ,Goldin J ,Kuizon BD , et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-1483
Full Text | Web of Science | Medline8
Raggi P ,Boulay A ,Chasan-Taber S , et al. Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695-701
CrossRef | Web of Science | Medline9
Ganesh SK ,Stack AG ,Levin NW ,Hulbert-Shearon T ,Port FK . Association of elevated serum PO4, Ca × PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-2138
Web of Science | Medline10
Block GA ,Port FK . Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000;35:1226-1237
CrossRef | Web of Science | Medline11
Johnson CA ,McCarthy J ,Bailie GR ,Deane J ,Smith S . Analysis of renal bone disease treatment in dialysis patients. Am J Kidney Dis 2002;39:1270-1277
CrossRef | Web of Science | Medline12
Indridason OS ,Quarles LD . Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Kidney Int 2000;57:282-292
CrossRef | Web of Science | Medline13
Maung HM ,Elangovan L ,Frazao JM , et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D2) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001;37:532-543
CrossRef | Web of Science | Medline14
Brown EM ,Gamba G ,Riccardi D , et al. Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature 1993;366:575-580
CrossRef | Web of Science | Medline15
Nemeth EF ,Steffey ME ,Hammerland LG , et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci U S A 1998;95:4040-4045
CrossRef | Web of Science | Medline16
Hammerland LG ,Garrett JE ,Hung BC ,Levinthal C ,Nemeth EF . Allosteric activation of the Ca2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol 1998;53:1083-1088
Web of Science | Medline17
Fox J ,Lowe SH ,Conklin RL ,Nemeth EF . The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism. Endocrine 1999;10:97-103
CrossRef | Web of Science | Medline18
Goodman WG ,Frazao JM ,Goodkin DA ,Turner SA ,Liu W ,Coburn JW . A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000;58:436-445
CrossRef | Web of Science | Medline19
Silverberg SJ ,Bone HG III ,Marriott TB , et al. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 1997;337:1506-1510
Full Text | Web of Science | Medline20
Brown EM . Mechanisms underlying the regulation of parathyroid hormone secretion in vivo and in vitro. Curr Opin Nephrol Hypertens 1993;2:541-551
CrossRef | Medline21
Goodman WG ,Hladik GA ,Turner SA , et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002;13:1017-1024
Web of Science | Medline22
Quarles LD ,Sherrard DJ ,Adler S , et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003;14:575-583
CrossRef | Web of Science | Medline23
Lindberg JS ,Moe SM ,Goodman WG , et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism. Kidney Int 2003;63:248-254
CrossRef | Web of Science | Medline24
Larsson L ,Ohman S . Serum ionized calcium and corrected total calcium in borderline hyperparathyroidism. Clin Chem 1978;24:1962-1965
Web of Science | Medline25
Nussbaum SR ,Zahradnik RJ ,Lavigne JR , et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987;33:1364-1367
Web of Science | Medline26
Kuritz SJ ,Landis JR ,Koch GG . A general overview of Mantel-Haenszel methods: applications and recent developments. Annu Rev Public Health 1988;9:123-160
CrossRef | Web of Science | Medline27
Wang M ,Hercz G ,Sherrard DJ ,Maloney NA ,Serge GV ,Pei Y . Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995;26:836-844
CrossRef | Web of Science | Medline28
Goodman WG . Recent developments in the management of secondary hyperparathyroidism. Kidney Int 2001;59:1187-1201
CrossRef | Web of Science | Medline29
Hsu CH . Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 1997;29:641-649
CrossRef | Web of Science | Medline30
Locatelli F ,Cannata-Andia JB ,Drueke TB , et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 2002;17:723-731
CrossRef | Web of Science | Medline31
National Kidney Foundation
CrossRef | Web of Science | Medline
- Citing Articles (296)
Citing Articles
1
Rob Boer, Anjana M. Lalla, Vasily Belozeroff. (2012) COST-EFFECTIVENESS OF CINACALCET IN SECONDARY HYPERPARATHYROIDISM IN THE UNITED STATES. Journal of Medical Economics1-38
CrossRef2
Bojan Kovacevic, Mile Ignjatovic, Vladan Zivaljevic, Vladimir Cuk, Milena Scepanovic, Zaklina Petrovic, Ivan Paunovic. (2012) Parathyroidectomy for the attainment of NKF-K/DOQI™ and KDIGO recommended values for bone and mineral metabolism in dialysis patients with uncontrollable secondary hyperparathyroidism. Langenbeck's Archives of Surgery
CrossRef3
Patricia A. Schenck, Dennis J. Chew, Larry A. Nagode, Thomas J. Rosol. 2012. Disorders of Calcium. , 120-194.
CrossRef4
Ralph Schneider, Emily P. Slater, Elias Karakas, Detlef K. Bartsch, Katja Schlosser. (2011) Initial Parathyroid Surgery in 606 Patients with Renal Hyperparathyroidism. World Journal of Surgery
CrossRef5
Mitchell H. Rosner, Joshua King, Peter Monteleone. 2011. Therapeutic Drug Development for Kidney Diseases. .
CrossRef6
David P. Macfarlane, Ning Yu, Peter T. Donnan, Graham P. Leese. (2011) Should ‘Mild Primary Hyperparathyroidism’ be reclassified as ‘insidious’: is it time to reconsider?. Clinical Endocrinology 75:6, 730-737
CrossRef7
Fellype Carvalho Barreto, Rodrigo Azevedo de Oliveira, Rodrigo Bueno Oliveira, Vanda Jorgetti. (2011) Pharmacotherapy of chronic kidney disease and mineral bone disorder. Expert Opinion on Pharmacotherapy 12:17, 2627-2640
CrossRef8
Eid M El-Shafey, Ali E Alsahow, Khalid Alsaran, Alaa A Sabry, Mohamed Atia. (2011) Cinacalcet Hydrochloride Therapy for Secondary Hyperparathyroidism in Hemodialysis Patients. Therapeutic Apheresis and Dialysis 15:6, 547-555
CrossRef9
Glenn M. Chertow, Z. John Lu, Xiao Xu, Tyler G. Knight, William G. Goodman, David A. Bushinsky, Geoffrey A. Block. (2011) Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols. Hemodialysis Internationaln/a-n/a
CrossRef10
Andrew Lee, Xue Song, Irfan Khan, Vasily Belozeroff, William Goodman, Nicole Fulcher, David Diakun. (2011) Association of cinacalcet adherence and costs in patients on dialysis. Journal of Medical Economics 14:6, 798-804
CrossRef11
H. Komaba, M. Koizumi, H. Tanaka, H. Takahashi, K. Sawada, T. Kakuta, M. Fukagawa. (2011) Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism. Nephrology Dialysis Transplantation
CrossRef12
Guillaume Jean. (2011) Comment je traite les troubles phosphocalciques en cas d’insuffisance rénale chronique. La Presse Médicale 40:11, 1043-1052
CrossRef13
NICHOLAS A GRAY, RATHIKA KRISHNASAMY, DEEPAK L VARDESH, PETER R HOLLETT, CHRIS M ANSTEY. (2011) Impact of non-traditional phosphate binders and cinacalcet on haemodialysis patient biochemistry, pill burden and cost. Nephrology 16:8, 688-696
CrossRef14
G. Miller, J. Davis, E. Shatzen, M. Colloton, D. Martin, C. M. Henley. (2011) Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD. Nephrology Dialysis Transplantation
CrossRef15
Masahiro Yamamoto, Hiroaki Ogata, Masahide Mizobuchi, Noriyo Yoshida, Chiaki Kumata-Maeta, Fumihiko Koiwa, Kanji Shishido, Eriko Kinugasa. (2011) Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism. Clinical and Experimental Nephrology
CrossRef16
Kentaro Wada, Yuko Wada, Yasuhiko Iino. (2011) Two cases of acute renal hemorrhage undergoing maintenance hemodialysis after concurrent administration of cinacalcet. Clinical and Experimental Nephrology 15:5, 783-787
CrossRef17
Sanela Smajilovic, Shozo Yano, Reza Jabbari, Jacob Tfelt-Hansen. (2011) The calcium-sensing receptor and calcimimetics in blood pressure modulation. British Journal of Pharmacology 164:3, 884-893
CrossRef18
Pieter Evenepoel, Ben Sprangers, Evelyne Lerut, Bert Bammens, Kathleen Claes, Dirk Kuypers, Björn Meijers, Yves Vanrenterghem. (2011) Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study. Clinical Transplantationno-no
CrossRef19
M. Ketteler, K. J. Martin, M. Cozzolino, D. Goldsmith, A. Sharma, S. Khan, E. Dumas, M. Amdahl, S. Marx, P. Audhya. (2011) Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. Nephrology Dialysis Transplantation
CrossRef20
Greg L. Plosker. (2011) Cinacalcet. PharmacoEconomics 29:9, 807-821
CrossRef21
Tomasz Hryszko, Szymon Brzosko, Alicja Rydzewska-Rosolowska, Ewa Koc-Zorawska, Michal Mysliwiec. (2011) Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism. International Urology and Nephrology
CrossRef22
Hirotaka Komaba, Takatoshi Kakuta, Masafumi Fukagawa. (2011) Diseases of the parathyroid gland in chronic kidney disease. Clinical and Experimental Nephrology
CrossRef23
Chetan Vedvyas, Laura S. Winterfield, Ruth Ann Vleugels. (2011) Calciphylaxis: A systematic review of existing and emerging therapies. Journal of the American Academy of Dermatology
CrossRef24
Yoshiyuki Oshiro, Hisataka Tanaka, Niro Okimoto. (2011) A patient undergoing chronic dialysis whose renal anemia was successfully corrected by treatment with cinacalcet. Clinical and Experimental Nephrology 15:4, 607-610
CrossRef25
Maria Fusaro, Angela D’Angelo, Agostino Naso, Anna Chiara Frigo, Davide Miozzo, Maurizio Gallieni, Lorenzo A. Calò. (2011) Treatment with Calcimimetic (Cinacalcet) Alters Epoetin Dosage Requirements in Dialysis Patients: Preliminary Report. Renal Failure 33:7, 732-735
CrossRef26
Leonardo Lucchi, Chiara Carboni, Lucia Stipo, Vittoria Malaguti, Federica Ferrari, Romina Graziani, Silvia Arletti, Catia Graziosi. (2011) Early Initiation of Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients: A Three-Year Clinical Experience. Artificial Organsno-no
CrossRef27
Markus Ketteler, Hansjörg Rothe, Thilo Krüger, Patrick H. Biggar, Georg Schlieper. (2011) Mechanisms and treatment of extraosseous calcification in chronic kidney disease. Nature Reviews Nephrology
CrossRef28
M. Koizumi, H. Komaba, S. Nakanishi, A. Fujimori, M. Fukagawa. (2011) Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrology Dialysis Transplantation
CrossRef29
Yasuo Imanishi, Takehisa Kawata, Takao Kenko, Michihito Wada, Nobuo Nagano, Takami Miki, Andrew Arnold, Masaaki Inaba. (2011) Cinacalcet HCl Suppresses Cyclin D1 Oncogene-Derived Parathyroid Cell Proliferation in a Murine Model for Primary Hyperparathyroidism. Calcified Tissue International 89:1, 29-35
CrossRef30
Manabu Okada, Yoshihiro Tominaga, Kumiko Izumi, Hironobu Nobata, Takayuki Yamamoto, Takahisa Hiramitsu, Makoto Tsujita, Norihiko Goto, Koji Nanmoku, Toshihiko Watarai, Kazuharu Uchida. (2011) Tertiary Hyperparathyroidism Resistant to Cinacalcet Treatment. Therapeutic Apheresis and Dialysis 15, 33-37
CrossRef31
Hisae Tanaka, Hirotaka Komaba, Masahiro Koizumi, Takatoshi Kakuta, Masafumi Fukagawa. (2011) Novel Electrochemiluminescence Immunoassay Exclusively for Full-length Parathyroid Hormone during Treatment with Cinacalcet for Secondary Hyperparathyroidism. Therapeutic Apheresis and Dialysis 15, 56-61
CrossRef32
David J. A. Goldsmith, John Cunningham. (2011) Mineral metabolism and vitamin D in chronic kidney disease—more questions than answers. Nature Reviews Nephrology 7:6, 341-346
CrossRef33
Leonidas H. Duntas, Nikolaos Stathatos. (2011) Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects. Endocrine 39:3, 199-204
CrossRef34
Jason R. Stubbs, James B. Wetmore. (2011) Does it Matter How Parathyroid Hormone Levels are Suppressed in Secondary Hyperparathyroidism?. Seminars in Dialysis 24:3, 298-306
CrossRef35
Donald T Ward, Daniela Riccardi. (2011) NEW CONCEPTS IN CALCIUM-SENSING RECEPTOR PHARMACOLOGY AND SIGNALLING. British Journal of Pharmacologyno-no
CrossRef36
G. Mercadal Orfila, I. Blasco Mascaró. (2011) Evaluación retrospectiva de la efectividad y seguridad de cinacalcet para el tratamiento de hiperparatiroidismo secundario dependiendo del valor basal de paratohormona intacta. Farmacia Hospitalaria
CrossRef37
Anders Fernström, Jan Giæver, Barbara Granroth, Britta Hylander, Gert Jensen, Anders Christensson, Björn Wikström, Lars Weiss, Ulf Wrege, Stefan H. Jacobson. (2011) Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: An observational study. Scandinavian Journal of Urology and Nephrology 45:3, 196-205
CrossRef38
Eid Mohamed El-Shafey, Ali Eid Alsahow, Gamal Fathy El-Nagar, Amal Ezzat. (2011) Intravenous Alfacalcidol Once Weekly Pulse Therapy for Secondary Hyperparathyroidism in Hemodialysis Patients. Renal Failure 33:3, 329-333
CrossRef39
P. Raggi, G. M. Chertow, P. U. Torres, B. Csiky, A. Naso, K. Nossuli, M. Moustafa, W. G. Goodman, N. Lopez, G. Downey, B. Dehmel, J. Floege, . (2011) The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrology Dialysis Transplantation 26:4, 1327-1339
CrossRef40
Peter Vestergaard. (2011) How may osteoporosis be prevented in individuals with diabetes?. Diabetes Management 1:2, 201-207
CrossRef41
M. Kurajoh, M. Inaba, S. Okuno, H. Nagayama, S. Yamada, Y. Imanishi, E. Ishimura, S. Shoji, T. Yamakawa, Y. Nishizawa. (2011) Reduction of whole PTH/intact PTH ratio as a predictor of bone metabolism in cinacalcet treatment of hemodialysis patients with secondary hyperparathyroidism. Osteoporosis International 22:3, 923-930
CrossRef42
Anke Schwarz, Saskia Merkel, Holger Leitolf, Hermann Haller. (2011) The Effect of Cinacalcet on Bone Remodeling and Renal Function in Transplant Patients With Persistent Hyperparathyroidism. Transplantation 91:5, 560-565
CrossRef43
M. Alcolea Palafox, P. Posada-Moreno, A. L. Villarino-Marín, C. Martinez-Rincon, I. Ortuño-Soriano, I. Zaragoza-García. (2011) DFT calculation of four new potential agents muscarinic of bispyridinium type: structure, synthesis, biological activity, hydration, and relations with the potents W84 and DUO-3O. Journal of Computer-Aided Molecular Design 25:2, 145-161
CrossRef44
John B. Copley, Rudolf P. Wüthrich. (2011) Therapeutic management of post-kidney transplant hyperparathyroidism. Clinical Transplantation 25:1, 24-39
CrossRef45
Emanuel Zitt, Christine Jäger, Alexander R. Rosenkranz, Manfred Eigner, Katharina Kodras, Josef Kovarik, Helmut Graf, Frank Pétavy, Sabine Horn, Bruno Watschinger. (2011) Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients – Results of the Austrian cohort of the ECHO study. Wiener klinische Wochenschrift 123:1-2, 45-52
CrossRef46
Sophie A. Jamal, Anthony B. Hodsman. (2011) Reducing the Risk of Re-Fracture in the Dialysis Population: Is it Time to Consider Therapy with PTH Analogues?. Seminars in Dialysis 24:1, 12-15
CrossRef47
Jana Henschkowski, Heike A. Bischoff-Ferrari, Rudolf P. Wüthrich, Andreas L. Serra. (2011) Renal Function in Patients Treated with Cinacalcet for Persistent Hyperparathyroidism after Kidney Transplantation. Kidney and Blood Pressure Research 34:2, 97-103
CrossRef48
Kanako Shibata, Yasuhiko Ito, Masashi Mizuno, Yasuhiro Suzuki, Hideki Hiramatsu, Isao Ito, Susumu Toda, Shoichi Maruyama, Seiichi Matsuo. (2011) Effects of cinacalcet on magnesium and potassium metabolism in peritoneal dialysis patients with residual renal function. Nihon Toseki Igakkai Zasshi 44:10, 1007-1013
CrossRef49
Edward M. Brown. 2011. Vitamin D and the Calcium-Sensing Receptor. , 425-456.
CrossRef50
Linda A. Russell. (2010) Osteoporosis and Osteomalacia. Rheumatic Disease Clinics of North America 36:4, 665-680
CrossRef51
V. Shalhoub, E.M. Shatzen, S.C. Ward, J-I. Young, M. Boedigheimer, L. Twehues, J. McNinch, S. Scully, B. Twomey, D. Baker, P. Kiaei, M.A. Damore, Z. Pan, K. Haas, D. Martin. (2010) Chondro/osteoblastic and cardiovascular gene modulation in human artery smooth muscle cells that calcify in the presence of phosphate and calcitriol or paricalcitol. Journal of Cellular Biochemistry 111:4, 911-921
CrossRef52
F. Hacard, O. Grézard, N. El Khoury, F. Maître, M. Delaplace, E. Estève. (2010) Calcinose diffuse de l’insuffisant rénal terminal. Annales de Dermatologie et de Vénéréologie 137:11, 759-760
CrossRef53
Mario Eandi, Lorenzo Pradelli, Sergio Iannazzo, Silvia Chiroli, Giuseppe Pontoriero. (2010) Economic Evaluation of Cinacalcet in the Treatment of Secondary Hyperparathyroidism in Italy. PharmacoEconomics 28:11, 1041-1054
CrossRef54
J. Feng, C. D. Petersen, D. H. Coy, J.-K. Jiang, C. J. Thomas, M. R. Pollak, S. A. Wank. (2010) Calcium-sensing receptor is a physiologic multimodal chemosensor regulating gastric G-cell growth and gastrin secretion. Proceedings of the National Academy of Sciences 107:41, 17791-17796
CrossRef55
Richard B. Mailman, Kent E. Vrana. 2010. Chemical Perspective on Neurotransmission and Drug Discovery for the Central Nervous System. .
CrossRef56
Geoffrey A Block, David Zaun, Gerard Smits, Martha Persky, Stephanie Brillhart, Kimberly Nieman, Jiannong Liu, Wendy L St Peter. (2010) Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney International 78:6, 578-589
CrossRef57
Neal Mittman, Brinda Desiraju, Kevin B Meyer, Jyoti Chattopadhyay, Morrell M Avram. (2010) Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study. Kidney International 78, S33-S36
CrossRef58
Edward M. Brown. (2010) Clinical utility of calcimimetics targeting the extracellular calcium-sensing receptor (CaSR). Biochemical Pharmacology 80:3, 297-307
CrossRef59
Ishir Bhan, Anil Dubey, Myles Wolf. (2010) Diagnosis and Management of Mineral Metabolism in CKD. Journal of General Internal Medicine 25:7, 710-716
CrossRef60
J. Floege, P. Raggi, G. A. Block, P. U. Torres, B. Csiky, A. Naso, K. Nossuli, M. Moustafa, W. G. Goodman, N. Lopez, G. Downey, B. Dehmel, G. M. Chertow, . (2010) Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. Nephrology Dialysis Transplantation 25:6, 1916-1923
CrossRef61
P. Dattolo, S. Michelassi, G. Simone, G. Ferro, F. Pizzarelli. (2010) Cinacalcet is effective in the treatment of hyperparathyroidism secondary to malignant transformation of autotransplanted parathyroid tissue. A case report. NDT Plus 3:3, 276-278
CrossRef62
Masao Koshikawa, Kensuke Nishiguchi, Soshi Yorifuji, Keiji Shimazu, Koji Takaori, Keita Mori, Eriko Eguchi, Kikuo Okada, Atsuo Tanaka, Takashi Kuwahara. (2010) Amino terminal cleavage of PTH(1–84) to PTH(7–84) is regulated by serum calcium concentration via calcium-sensing receptor in hemodialysis patients. Clinical and Experimental Nephrology 14:3, 233-238
CrossRef63
Geoffrey A. Block. (2010) Screening Dialysis Patients for Vascular Calcification. Seminars in Dialysis 23:3, 271-276
CrossRef64
Carlo Vulpio, Maurizio Bossola, Annamaria De Gaetano, Giulia Maresca, Enrico Di Stasio, Luca Zagaria, Giovanna Luciani, Alessandro Giordano, Marco Castagneto. (2010) Parathyroid Gland Ultrasound Patterns and Biochemical Findings After One-year Cinacalcet Treatment for Advanced Secondary Hyperparathyroidism. Therapeutic Apheresis and Dialysis 14:2, 178-185
CrossRef65
Solenne Pelletier, Roland Chapurlat. (2010) Optimizing bone health in chronic kidney disease. Maturitas 65:4, 325-333
CrossRef66
Jorge B. Cannata-Andía, Minerva Rodriguez-García, Pablo Román-García, Diego Tuñón-le Poultel, Francisco López-Hernández, Diego Rodríguez-Puyol. (2010) New therapies: calcimimetics, phosphate binders and vitamin D receptor activators. Pediatric Nephrology 25:4, 609-616
CrossRef67
Behnam Tehrani, Oliver Szeto, Chayan Chakraborti. (2010) Lower extremity ulcers and the satisfied search. Journal of Hospital Medicine 5:3, E31-E32
CrossRef68
Daniel Álvarez-Hernández, Ignacio González-Suárez, José L. Fernández-Martín, Isabel Rodríguez, Íñigo Santamaría, Eliecer Coto, Jorge B. Cannata-Andía. (2010) Residue 826 in the Calcium-Sensing Receptor Is Implicated in the Response to Calcium and to R-568 Calcimimetic Compound. Calcified Tissue International 86:3, 227-233
CrossRef69
Elif Hindié, Paolo Zanotti-Fregonara, Pierre-Alexandre Just, Emile Sarfati, Didier Mellière, Marie-Elisabeth Toubert, Jean-Luc Moretti, Christian Jeanguillaume, Isabelle Keller, Pablo Ureña-Torres. (2010) Parathyroid scintigraphy findings in chronic kidney disease patients with recurrent hyperparathyroidism. European Journal of Nuclear Medicine and Molecular Imaging 37:3, 623-634
CrossRef70
Kathryn M. Ruf, Timothy Clifford, Kelly M. Smith. (2010) Management of Chronic Kidney Disease–Mineral Bone Disorder. Orthopedics 33:2, 98-101
CrossRef71
H. Komaba, J. Shin, M. Fukagawa. (2010) Restoration of reversed whole PTH/intact PTH ratio and reduction in parathyroid gland vascularity during cinacalcet therapy for severe hyperparathyroidism in a uraemic patient. Nephrology Dialysis Transplantation 25:2, 638-641
CrossRef72
M. Jadoul, A. Banos, V. J. Zani, G. Hercz. (2010) The effects of discontinuing cinacalcet at the time of kidney transplantation. NDT Plus 3:1, 37-41
CrossRef73
Christian P. Karger, Vedat Schwenger, Claudia Sommerer, Martin Zeier. (2010) Synergistic effect of cinacalcet and active vitamin D in a dialysis patient with secondary hyperparathyroidism. Dialysis & Transplantation 39:2, 69-71
CrossRef74
Caroline Platt, Carol Inward, Mary McGraw, Jan Dudley, Jane Tizard, Christine Burren, Moin A. Saleem. (2010) Middle-term use of Cinacalcet in paediatric dialysis patients. Pediatric Nephrology 25:1, 143-148
CrossRef75
Kazuo Fukumoto, Tomonaga Noguchi, Sayoko Toriie, Eiichi Shimazu, Susumu Miyake. (2010) The mechanism of upper-gastrointestinal complication after taking cinacalcet hydrochloride. Nihon Toseki Igakkai Zasshi 43:3, 309-315
CrossRef76
Vassilis Vargemezis, Vassilios Liakopoulos, Pelagia Kriki, Stylianos Panagoutsos, Maria Leontsini, Ploumis Passadakis, Elias Thodis. (2010) Pivotal Role of Paricalcitol in the Treatment of Calcific Uremic Arteriolopathy in the Presence of a Parathyroid Adenoma. American Journal of Kidney Diseases 55:1, 144-147
CrossRef77
Piergiorgio Bolasco, Alessandra Serra, Maurizio Loi, Andrea Galfré, Mario Piga. (2010) Failed Switching off in the MIBI-Parathyroid Scintigraphy in a Dialyzed Patient with Secondary Hyperparathyroidism Responsive to Cinacalcet Therapy. International Journal of Endocrinology 2010, 1-5
CrossRef78
Shozo Yano, Keiko Suzuki, Masaaki Sumi, Akihide Tokumoto, Kazushi Shigeno, Yasutoshi Himeno, Toshitsugu Sugimoto. (2010) Bone metabolism after cinacalcet administration in patients with secondary hyperparathyroidism. Journal of Bone and Mineral Metabolism 28:1, 49-54
CrossRef79
Keiichi Ozono. (2010) A bone-kidney axis: New concept. Nihon Shoni Jinzobyo Gakkai Zasshi 23:2, 189-194
CrossRef80
Nadezda Koleganova, Grzegorz Piecha, Eberhard Ritz. (2010) Vasculotropic effects of calcimimetics. Current Opinion in Nephrology and Hypertension 19:1, 32-36
CrossRef81
David Fuster, José-Vicente Torregrosa, Beatriz Domenech, Oriol Solà, Gloria Martín, Joan Casellas, Xavier Setoain, Africa Muxí, Francesca Pons. (2009) Dual-phase 99mTc-MIBI scintigraphy to assess calcimimetic effect in patients on haemodialysis with secondary hyperparathyroidism. Nuclear Medicine Communications 30:11, 890-894
CrossRef82
Yasuo Imanishi, Masaaki Inaba, Takehisa Kawata, Yoshiki Nishizawa. (2009) Cinacalcet in Hyperfunctioning Parathyroid Diseases. Therapeutic Apheresis and Dialysis 13, S7-S11
CrossRef83
Susan C. Pitt, Rebecca S. Sippel, Herbert Chen. (2009) Secondary and Tertiary Hyperparathyroidism, State of the Art Surgical Management. Surgical Clinics of North America 89:5, 1227-1239
CrossRef84
Kentaro Nakai, Hirotaka Komaba, Masafumi Fukagawa. (2009) Management of Mineral and Bone Disorder in Chronic Kidney Disease: Quo Vadis?. Therapeutic Apheresis and Dialysis 13, S2-S6
CrossRef85
Rajiv Kumar. (2009) Pin1 regulates parathyroid hormone mRNA stability. Journal of Clinical Investigation 119:10, 2887-2891
CrossRef86
Hirotaka Komaba, Kensuke Moriwaki, Isao Kamae, Masafumi Fukagawa. (2009) Towards Cost-effective Strategies for Treatment of Chronic Kidney Disease-Mineral and Bone Disorder in Japan. Therapeutic Apheresis and Dialysis 13, S28-S35
CrossRef87
Takatoshi Kakuta, Reika Tanaka, Genta Kanai, Asako Sawaya, Takashi Hirukawa, Atsuhiro Sato, Akira Saito. (2009) Can Cinacalcet Replace Parathyroid Intervention in Severe Secondary Hyperparathyroidism?. Therapeutic Apheresis and Dialysis 13, S20-S27
CrossRef88
T. B. Drueke, M. Touam. (2009) Calcium balance in haemodialysis--do not lower the dialysate calcium concentration too much (con part). Nephrology Dialysis Transplantation 24:10, 2990-2993
CrossRef89
J. Braun. (2009) Kalziumhaushalt und Kalzimimetika-Therapie. Der Nephrologe 4:5, 411-417
CrossRef90
P. Urena, S. H. Jacobson, E. Zitt, M. Vervloet, F. Malberti, N. Ashman, S. Leavey, M. Rix, I. Os, H. Saha, M. Ryba, V. Bencova, A. Banos, V. Zani, D. Fouque. (2009) Cinacalcet and achievement of the NKF/K-DOQITM recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study. Nephrology Dialysis Transplantation 24:9, 2852-2859
CrossRef91
George Giannikopoulos, Markela-Pagonitsa Zorzou, Ioannis Stamoulis, Georgia Panagi, Panagiotis Sitaras, Ioannis Georgopoulos, Constantinos Hadjileontis, Ioannis Malakos, John Kyriazis. (2009) Cinacalcet-Induced Leukocytoclastic Vasculitis. American Journal of Kidney Diseases 54:2, e5-e8
CrossRef92
Charles Henley, James Davis, Gerald Miller, Edward Shatzen, Russ Cattley, Xiaodong Li, David Martin, Wei Yao, Nancy Lane, Victoria Shalhoub. (2009) The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats. European Journal of Pharmacology 616:1-3, 306-313
CrossRef93
Wen T. Shen, Electron Kebebew, Insoo Suh, Quan-Yang Duh, Orlo H. Clark. (2009) Two hundred and two consecutive operations for secondary hyperparathyroidism: Has medical management changed the profiles of patients requiring parathyroidectomy?. Surgery 146:2, 296-299
CrossRef94
(2009) Chapter 4.1: Treatment of CKD–MBD targeted at lowering high serum phosphorus and maintaining serum calcium. Kidney International 76, S50-S99
CrossRef95
Andrew M. Peck. (2009) Calcimimetics: A Review of the Recent Literature. Kidney 18:4, 175-179
CrossRef96
B. Schiller, A. Wong, M. Blair, J. Moran. (2009) False low parathyroid hormone values secondary to sample contamination with the tissue plasminogen activator. Nephrology Dialysis Transplantation 24:7, 2240-2243
CrossRef97
Ognen Ivanovski, Igor G. Nikolov, Nobuhiko Joki, Axelle Caudrillier, Olivier Phan, Romuald Mentaverri, Julien Maizel, Yasuhiro Hamada, Thao Nguyen-Khoa, Masafumi Fukagawa, Said Kamel, Bernard Lacour, Tilman B. Drüeke, Ziad A. Massy. (2009) The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE−/−) mice. Atherosclerosis 205:1, 55-62
CrossRef98
Goce Spasovski, Ziad Massy, Raymond Vanholder. (2009) Phosphate Metabolism in Chronic Kidney Disease: From Pathophysiology to Clinical Management. Seminars in Dialysis 22:4, 357-362
CrossRef99
Laura Byham-Gray, Tammy Drasher, Karen Deckman, Diane Graham, Carol Liftman, Linda Roberto, Phyllis Peiffer, Robert Denmark. (2009) Effect of Aggressive Osteodystrophy Management on Clinical Outcomes in Stage 5 Chronic Kidney Disease. Journal of Renal Nutrition 19:4, 321-333
CrossRef100
Katherine Wesseling-Perry, G. Chris Harkins, He-Jing Wang, Shobha Sahney, Barbara Gales, Robert M. Elashoff, Harald Jüppner, Isidro B. Salusky. (2009) Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols. Pediatric Nephrology 24:7, 1355-1361
CrossRef101
Nobuhiko Joki, Igor G. Nikolov, Axelle Caudrillier, Romuald Mentaverri, Ziad A. Massy, Tilman B. Drüeke. (2009) Effects of calcimimetic on vascular calcification and atherosclerosis in uremic mice. Bone 45, S30-S34
CrossRef102
STACEY O'SHEA, DAVID W JOHNSON. (2009) Review article: Addressing risk factors in chronic kidney disease mineral and bone disorder: Can we influence patient-level outcomes?. Nephrology 14:4, 416-427
CrossRef103
PETER A MCCULLOUGH, MOHIT AGARWAL, VARUN AGRAWAL. (2009) Review article: Risks of coronary artery calcification in chronic kidney disease: Do the same rules apply?. Nephrology 14:4, 428-436
CrossRef104
Mario Cozzolino, Maurizio Gallieni, Sabina Pasho, Giuditta Fallabrino, Paola Ciceri, Elisa Maria Volpi, Laura Olivi, Diego Brancaccio. (2009) Management of Secondary Hyperparathyroidism in the Elderly Patient with Chronic Kidney Disease. Drugs & Aging 26:6, 457-468
CrossRef105
Pieter Evenepoel. (2009) When is Vitamin D Contraindicated in Dialysis Patients?. Seminars in Dialysis 22:3, 242-244
CrossRef106
Desmond Padhi, Robert Harris. (2009) Clinical Pharmacokinetic and Pharmacodynamic Profile of Cinacalcet Hydrochloride. Clinical Pharmacokinetics 48:5, 303-311
CrossRef107
James Tomlinson, John Cunningham. (2009) SOFT BONES AND HARD ARTERIES-CAN WE REVERSE THE TREND IN CKD?. Journal of Renal Care 35, 28-33
CrossRef108
Tejas V. Patel, Ajay K. Singh. (2009) Kidney Disease Outcomes Quality Initiative Guidelines for Bone and Mineral Metabolism: Emerging Questions. Seminars in Nephrology 29:2, 105-112
CrossRef109
Jordi Bover, Neus Farré, Enric Andrés, Cristina Canal, María Teresa Olaya, Maite Alonso, Begoña Quílez, José Ballarín. (2009) UPDATE ON THE TREATMENT OF CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER. Journal of Renal Care 35, 19-27
CrossRef110
Francesco TONELLI, Tommaso MARCUCCI, Francesco GIUDICI, Alberto FALCHETTI, Maria Luisa BRANDI. (2009) Surgical Approach in Hereditary Hyperparathyroidism. Endocrine Journal 56:7, 827-841
CrossRef111
Karin Weber, Ute Zeitz, Claudia Bergow, Sieglinde Hirmer, Christiane Schüler, Reinhold G Erben. (2009) Vitamin D–Independent Therapeutic Effects of Extracellular Calcium in a Mouse Model of Adult-Onset Secondary Hyperparathyroidism. Journal of Bone and Mineral Research 24:1, 22-32
CrossRef112
Thomas Bardin, Pascal Richette. (2009) Rheumatic manifestations of renal disease. Current Opinion in Rheumatology 21:1, 55-61
CrossRef113
James B Wetmore, L Darryl Quarles. (2009) Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?. Nature Clinical Practice Nephrology 5:1, 24-33
CrossRef114
Marco De Amici, Clelia Dallanoce, Ulrike Holzgrabe, Christian Tränkle, Klaus Mohr. (2009) Allosteric ligands for G protein-coupled receptors: A novel strategy with attractive therapeutic opportunities. Medicinal Research Reviewsn/a-n/a
CrossRef115
L. Ceglia, S. S. Harris, H. M. Rasmussen, B. Dawson-Hughes. (2009) Activation of the calcium sensing receptor stimulates gastrin and gastric acid secretion in healthy participants. Osteoporosis International 20:1, 71-78
CrossRef116
Kazumichi Matsushita, Hidehiro Tabata, Kosaku Nitta, Kiichiro Tago. (2009) Management of calcium by oral vitamin D analogs during calcimimetics therapy for secondary hyperparathyroidism. Nihon Toseki Igakkai Zasshi 42:11, 857-863
CrossRef117
Chihiro Kozu, Taku Furukubo, Chiharu Matsunaga, Sakiko Negoro, Satoshi Izumi, Senji Okuno, Kiyoshi Maekawa, Tadashi Yamamoto, Tomoyuki Yamakawa. (2009) Survey of adverse events during treatment with cinacalcet hydrochloride in dialysis patients with secondary hyperparathyroidism. Nihon Toseki Igakkai Zasshi 42:12, 931-938
CrossRef118
Piergiorgio Messa, Carlo Alfieri, Brigida Brezzi. (2008) Cinacalcet: pharmacological and clinical aspects. Expert Opinion on Drug Metabolism & Toxicology 4:12, 1551-1560
CrossRef119
Mariano Rodríguez, Escolástico Aguilera-Tejero, F Javier Mendoza, Fátima Guerrero, Ignacio López. (2008) Effects of calcimimetics on extraskeletal calcifications in chronic kidney disease. Kidney International 74, S50-S54
CrossRef120
M.-u. Alam, J. P. Kirton, F. L. Wilkinson, E. Towers, S. Sinha, M. Rouhi, T. N. Vizard, A. P. Sage, D. Martin, D. T. Ward, M. Y. Alexander, D. Riccardi, A. E. Canfield. (2008) Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovascular Research 81:2, 260-268
CrossRef121
H. Komaba, M. Fukagawa. (2008) Regression of parathyroid hyperplasia by calcimimetics--fact or illusion?. Nephrology Dialysis Transplantation 24:3, 707-709
CrossRef122
M. Meola, I. Petrucci, G. Barsotti. (2008) Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrology Dialysis Transplantation 24:3, 982-989
CrossRef123
Jutta Muscheites, Marianne Wigger, Erdmute Drueckler, Dagmar-Christiane Fischer, Guenther Kundt, Dieter Haffner. (2008) Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. Pediatric Nephrology 23:10, 1823-1829
CrossRef124
Yoshihiro Tominaga, Susumu Matsuoka, Nobuaki Uno, Tetsuhiko Sato. (2008) Parathyroidectomy for Secondary Hyperparathyroidism in the Era of Calcimimetics. Therapeutic Apheresis and Dialysis 12, S21-S26
CrossRef125
Hirotaka Komaba, Masafumi Fukagawa. (2008) Impact of Cinacalcet Hydrochloride on the Achievement of the Japanese Society for Dialysis Therapy (JSDT) Guideline Targets: A post-hoc Analysis of the KRN1493 Study. Therapeutic Apheresis and Dialysis 12, S44-S49
CrossRef126
Georg Schlieper, Jürgen Floege. (2008) Calcimimetics in CKD—results from recent clinical studies. Pediatric Nephrology 23:10, 1721-1728
CrossRef127
Tilman B Drüeke. (2008) Cinacalcet Treatment in Dialysis Patients with Secondary Hyperparathyroidism: Effects and Open Issues. Therapeutic Apheresis and Dialysis 12, S2-S12
CrossRef128
Douglas M. Silverstein, Kanwal K. Kher, Asha Moudgil, Mona Khurana, Jennifer Wilcox, Kathleen Moylan. (2008) Cinacalcet is efficacious in pediatric dialysis patients. Pediatric Nephrology 23:10, 1817-1822
CrossRef129
Joshua A. Ray, Rohit Borker, Beth Barber, William J. Valentine, Vasily Belozeroff, Andrew J. Palmer. (2008) Cost-Effectiveness of Early versus Late Cinacalcet Treatment in Addition to Standard Care for Secondary Renal Hyperparathyroidism in the USA. Value in Health 11:5, 800-808
CrossRef130
Margaret J Blayney, Ronald L Pisoni, Jennifer L Bragg-Gresham, Juergen Bommer, Luis Piera, Akira Saito, Takashi Akiba, Marcia L Keen, Eric W Young, Friedrich K Port. (2008) High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney International 74:5, 655-663
CrossRef131
Indra Ramasamy. (2008) Inherited disorders of calcium homeostasis. Clinica Chimica Acta 394:1-2, 22-41
CrossRef132
Pieter Evenepoel. (2008) Calcimimetics in chronic kidney disease: evidence, opportunities and challenges. Kidney International 74:3, 265-275
CrossRef133
Carlos Bergua, José-Vicente Torregrosa, David Fuster, Alex Gutierrez-Dalmau, Federico Oppenheimer, José M. Campistol. (2008) Effect of Cinacalcet on Hypercalcemia and Bone Mineral Density in Renal Transplanted Patients With Secondary Hyperparathyroidism. Transplantation 86:3, 413-417
CrossRef134
S. Goto, H. Komaba, M. Fukagawa. (2008) Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention. NDT Plus 1:Supplement 3, iii2-iii8
CrossRef135
H. Ogata, M. Mizobuchi, F. Koiwa, E. Kinugasa, T. Akizawa. (2008) Clinical significance of parathyroid intervention on CKD-MBD management. NDT Plus 1:Supplement 3, iii9-iii13
CrossRef136
M. Tanaka, S. Nakanishi, H. Komaba, K. Itoh, K. Matsushita, M. Fukagawa. (2008) Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism. NDT Plus 1:Supplement 3, iii49-iii53
CrossRef137
Angel LM de Francisco, Celestino Piñera, Rosa Palomar. (2008) Cinacalcet should be used to treat secondary hyperparathyroidism in stage 3–4 chronic kidney disease. Nature Clinical Practice Nephrology 4:7, 366-367
CrossRef138
Frédéric Triponez, Orlo H. Clark, Yves Vanrenthergem, Pieter Evenepoel. (2008) Surgical Treatment of Persistent Hyperparathyroidism After Renal Transplantation. Annals of Surgery 248:1, 18-30
CrossRef139
Leif Mosekilde. (2008) Primary hyperparathyroidism and the skeleton. Clinical Endocrinology 69:1, 1-19
CrossRef140
Udo Bahner, Margit Brandl, Christoph Nies, Heinrich Schmidt-Gayk. (2008) Use of Cinacalcet HCl to Achieve the Recommended Targets of Bone Metabolism in a Patient With Therapy-Resistant Renal Hyperparathyroidism. Journal of Renal Nutrition 18:4, 383-388
CrossRef141
C P Kovesdy, K Kalantar-Zadeh. (2008) Vitamin D receptor activation and survival in chronic kidney disease. Kidney International 73:12, 1355-1363
CrossRef142
Cheryl P. Sanchez. (2008) Mineral metabolism and bone abnormalities in children with chronic renal failure. Reviews in Endocrine and Metabolic Disorders 9:2, 131-137
CrossRef143
G. A. Block, S. Zeig, J. Sugihara, G. M. Chertow, E. M. Chi, S. A. Turner, D. A. Bushinsky, . (2008) Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrology Dialysis Transplantation 23:7, 2311-2318
CrossRef144
Ashwini R. Sehgal, Catherine Sullivan, Janeen B. Leon, Karil Bialostosky. (2008) Public Health Approach to Addressing Hyperphosphatemia Among Dialysis Patients. Journal of Renal Nutrition 18:3, 256-261
CrossRef145
Angel LM de Francisco. (2008) New strategies for the treatment of hyperparathyroidism incorporating calcimimetics. Expert Opinion on Pharmacotherapy 9:5, 795-811
CrossRef146
Nabieh Al-Hilali, Hani Al-Humoud, Bassam Al-Helal, Mohammed Al-Azmi, Nasser H Al-Kandari, Kaivilayil V Johny. (2008) Intravenous Alfacalcidol Once Weekly Suppresses Parathyroid Hormone in Hemodialysis Patients. Therapeutic Apheresis and Dialysis 12:2, 137-142
CrossRef147
Takashi Akiba, Tadao Akizawa, Yusuke Tsukamoto, Eiji Uchida, Manabu Iwasaki, Shozo Koshikawa, . (2008) Dose Determination of Cinacalcet Hydrochloride in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism. Therapeutic Apheresis and Dialysis 12:2, 117-125
CrossRef148
Hansjörg Rothe, Warren Shapiro, Wei Y Sun, Albert Matalon. (2008) CaSR polymorphism Arg990Gly and response to calcimimetic agents in end-stage kidney disease patients with secondary hyperparathyroidism and in cell culture. Personalized Medicine 5:2, 109-116
CrossRef149
M. Ketteler. (2008) Phosphatbinder, Vitamin D, Cinacalcet. Der Nephrologe 3:2, 96-107
CrossRef150
Ogo I. Egbuna, Edward M. Brown. (2008) Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. Best Practice & Research Clinical Rheumatology 22:1, 129-148
CrossRef151
Kunitoshi Iseki. (2008) Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan. Expert Opinion on Pharmacotherapy 9:4, 601-610
CrossRef152
PEDRO IGLESIAS, GUILLERMO AIS, ANA GONZÁLEZ, PILAR TAJADA, CARMEN GARCÍA ARÉVALO, ENRIQUE FERNÁNDEZ PARDO, JUAN J. DÍEZ. (2008) Acute and One-Year Effects of Cinacalcet in Patients With Persistent Primary Hyperparathyroidism After Unsuccessful Parathyroidectomy. The American Journal of the Medical Sciences 335:2, 111-114
CrossRef153
Katherine Wesseling, Sevcan Bakkaloglu, Isidro Salusky. (2008) Chronic kidney disease mineral and bone disorder in children. Pediatric Nephrology 23:2, 195-207
CrossRef154
I Lopez, F J Mendoza, E Aguilera-Tejero, J Perez, F Guerrero, D Martin, M Rodriguez. (2008) The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney International 73:3, 300-307
CrossRef155
Menno T. Pruijm, Daniel Teta, Grégoire Wuerzner, Valérie Santschi, Michel Burnier. (2008) Traitement de l’hyperparathyroïdisme secondaire en dialyse : à propos d’un cas d’inefficacité apparente du traitement médicamenteux. Néphrologie & Thérapeutique 4:1, 28-33
CrossRef156
RUBIN ZHANG, BRENT ALPER, ERIC SIMON, SANDY FLORMAN, DOUGLAS SLAKEY. (2008) Management of Metabolic Bone Disease in Kidney Transplant Recipients. The American Journal of the Medical Sciences 335:2, 120-125
CrossRef157
M.-H. Lafage-Proust. (2008) Osteodistrofia renal. EMC - Aparato Locomotor 41:4, 1-16
CrossRef158
Eberhard Ritz, Christoph Wanner. 2008. Cardiovascular Complications of End-Stage Renal Disease. , 773-782.
CrossRef159
Desmond Padhi, Robert Z Harris, Margaret Salfi, Robert J Noveck, John T Sullivan. (2008) Pharmacokinetics and Pharmacodynamics of Cinacalcet in Hepatic Impairment. Clinical Drug Investigation 28:10, 635-643
CrossRef160
Rizwan A. Qazi, Kevin J. Martin. 2008. Calcium, Phosphorus, Renal Bone Disease, and Calciphylaxis. , 765-772.
CrossRef161
Desmond Padhi, Maggi Salfi, Maurice Emery. (2008) Cinacalcet Does Not Affect the Activity of Cytochrome P450 3A Enzymes, a Metabolic Pathway for Common Immunosuppressive Agents. Drugs in R & D 9:5, 335-343
CrossRef162
Hirotaka Komaba, Motoko Tanaka, Masafumi Fukagawa. (2008) Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Internal Medicine 47:11, 989-994
CrossRef163
R. P. Wüthrich, D. Martin, J. P. Bilezikian. (2007) The role of calcimimetics in the treatment of hyperparathyroidism. European Journal of Clinical Investigation 37:12, 915-922
CrossRef164
Walter G. Douthat, Santiago E. Orozco, Pablo Maino, Gabriela Cardozo, Javier de Arteaga, Jorge de la Fuente, Carlos R. Chiurchiu, Pablo U. Massari. (2007) Percutaneous ethanol injection therapy in post-transplant patients with secondary hyperparathyroidism. Transplant International 20:12, 1031-1035
CrossRef165
Anca Gal-Moscovici, Stuart M. Sprague, Edgar V. Lerma. (2007) Treatment of renal osteodystrophy. Clinical Reviews in Bone and Mineral Metabolism 5:1, 27-38
CrossRef166
Hiroaki Ogata, Fumihiko Koiwa, Eriko Kinugasa, Tadao Akizawa. (2007) CKD-MBD: impact on management of kidney disease. Clinical and Experimental Nephrology 11:4, 261-268
CrossRef167
Goce B. Spasovski. (2007) Bone health and vascular calcification relationships in chronic kidney disease. International Urology and Nephrology 39:4, 1209-1216
CrossRef168
NIGEL D TOUSSAINT, PETER G KERR. (2007) Vascular calcification and arterial stiffness in chronic kidney disease: Implications and management. Nephrology 12:5, 500-509
CrossRef169
B. Festen-Spanjer, C. M. Haring, J. B. Koster, A. H. Mudde. (2007) Correction of hypercalcaemia by cinacalcet in familial hypocalciuric hypercalcaemia. Clinical Endocrinology 0:0, 070907132242013-???
CrossRef170
Luon W. Peng, Joy L. Logan, Sam H. James, Katherine M. Scott, Yeong-Hau Howard Lien. (2007) Cinacalcet-Associated Graft Dysfunction and Nephrocalcinosis in a Kidney Transplant Recipient. The American Journal of Medicine 120:9, e7-e9
CrossRef171
B. Kestenbaum, V. Belozeroff. (2007) Mineral metabolism disturbances in patients with chronic kidney disease. European Journal of Clinical Investigation 37:8, 607-622
CrossRef172
Naoki KIMATA, Justin M. ALBERT, Takashi AKIBA, Shin YAMAZAKI, Yoshindo KAWAGUCHI, Shunichi FUKUHARA, Tadao AKIZAWA, Akira SAITO, Yasushi ASANO, Kiyoshi KUROKAWA, Ronald L. PISONI, Friedrich K. PORT. (2007) Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: The Japan dialysis outcomes and practice patterns study. Hemodialysis International 11:3, 340-348
CrossRef173
Bryan Kestenbaum. (2007) PHOSPHORUS METABOLISM AND MANAGEMENT IN CHRONIC KIDNEY DISEASE: Phosphate Metabolism in the Setting of Chronic Kidney Disease: Significance and Recommendations for Treatment. Seminars in Dialysis 20:4, 286-294
CrossRef174
Keith A. Hruska, Georges Saab, Suresh Mathew, Richard Lund. (2007) PHOSPHORUS METABOLISM AND MANAGEMENT IN CHRONIC KIDNEY DISEASE: Renal Osteodystrophy, Phosphate Homeostasis, and Vascular Calcification. Seminars in Dialysis 20:4, 309-315
CrossRef175
Ziyad Al-Aly, Rizwan A. Qazi, Esther A. González, Angelique Zeringue, Kevin J. Martin. (2007) Changes in Serum 25-Hydroxyvitamin D and Plasma Intact PTH Levels Following Treatment With Ergocalciferol in Patients With CKD. American Journal of Kidney Diseases 50:1, 59-68
CrossRef176
Rajeev Narayan, Robert M. Perkins, Elizabeth P. Berbano, Christina M. Yuan, Robert T. Neff, Eric S. Sawyers, Fred E. Yeo, Gwenaelle M. Vidal-Trecan, Kevin C. Abbott. (2007) Parathyroidectomy Versus Cinacalcet Hydrochloride–Based Medical Therapy in the Management of Hyperparathyroidism in ESRD: A Cost Utility Analysis. American Journal of Kidney Diseases 49:6, 801-813
CrossRef177
Paul D. Miller. (2007) Is There a Role for Bisphosphonates in Chronic Kidney Disease?. Seminars in Dialysis 20:3, 186-190
CrossRef178
J.C. Ruiz San Millán, G. Fernández, M. Arias. (2007) Insuficiencia renal crónica (II). Medicine - Programa de Formación Médica Continuada Acreditado 9:79, 5077-5086
CrossRef179
Desmond Padhi, Margaret Salfi, Robert Z Harris. (2007) The Pharmacokinetics of Cinacalcet are Unaffected Following Consumption of High- and Low-Fat Meals. American Journal of Therapeutics 14:3, 235-240
CrossRef180
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Bazari, Hasan, Jaff, Michael R., Mannstadt, Michael, Yan, Shaofeng, . (2007) Case 7-2007. New England Journal of Medicine 356:10, 1049-1057
Full Text181
Adrian Covic, Paul Gusbeth-Tatomir, David J. A. Goldsmith. (2007) VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Vascular Calcification-A New Window on the Cardiovascular System: Role of Agents Used to Manipulate Skeletal Integrity. Seminars in Dialysis 20:2, 158-169
CrossRef182
Alex J. Brown. (2007) Vitamin D analogs for secondary hyperparathyroidism: What does the future hold?. The Journal of Steroid Biochemistry and Molecular Biology 103:3-5, 578-583
CrossRef183
Edward M Brown. (2007) Clinical lessons from the calcium-sensing receptor. Nature Clinical Practice Endocrinology & Metabolism 3:2, 122-133
CrossRef184
Robert Z. Harris, Margaret Salfi, Ed Posvar, David Hoelscher, Desmond Padhi. (2007) Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. European Journal of Clinical Pharmacology 63:2, 159-163
CrossRef185
A. Sparsa. (2007) Calcinosis, osificaciones y lesiones cartilaginosas cut??neas. EMC - Dermatolog??a 41:3, 1-19
CrossRef186
Eric S. Lazar, Nicole Stankus. (2007) Dialysis Rounds: Cinacalcet-Induced Hungry Bone Syndrome. Seminars in Dialysis 20:1, 83-85
CrossRef187
Eric Lazar, Katrina Hebert, Tammy Poma, Nicole Stankus. (2007) Long-Term Outcomes of Cinacalcet and Paricalcitol Titration Protocol for Treatment of Secondary Hyperparathyroidism. American Journal of Nephrology 27:3, 274-278
CrossRef188
Stephen Z. Fadem, Sharon M. Moe. (2007) Management of Chronic Kidney Disease Mineral-Bone Disorder. Advances in Chronic Kidney Disease 14:1, 44-53
CrossRef189
Robert Z Harris, Margaret Salfi, John T Sullivan, Desmond Padhi. (2007) Pharmacokinetics of Cinacalcet Hydrochloride When Administered with Ketoconazole. Clinical Pharmacokinetics 46:6, 495-501
CrossRef190
David A Bushinsky. (2007) Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism. Nature Clinical Practice Nephrology 3:1, 12-13
CrossRef191
John Cunningham. (2007) Opinion: Which of the K/DOQI Guidelines for Bone Disease in Dialysis Patients Should Be Changed?. Seminars in Dialysis 20:1, 30-32
CrossRef192
Diego Brancaccio, Jürgen Bommer, Daniel Coyne. (2007) Vitamin D Receptor Activator Selectivity in the Treatment of Secondary Hyperparathyroidism. Drugs 67:14, 1981-1998
CrossRef193
Michael R. Rickels, Jacqueline M. Junkins-Hopkins, Thomas S. Metkus, Nayyar Iqbal. (2007) Calcific Uremic Arteriolopathy (Calciphylaxis). The Endocrinologist 17:1, 57-62
CrossRef194
Dina E Green, Solomon Epstein. (2006) Parathyroids, bone and mineral metabolism. Current Opinion in Endocrinology and Diabetes 13:6, 503-508
CrossRef195
Sharon M Moe. (2006) Treatment of Chronic Kidney Disease?Mineral Bone Disorder and Vascular Complications. Therapeutic Apheresis and Dialysis 10:s1, S2-S15
CrossRef196
V. Shalhoub, E. Shatzen, C. Henley, M. Boedigheimer, J. McNinch, R. Manoukian, M. Damore, D. Fitzpatrick, K. Haas, B. Twomey, P. Kiaei, S. Ward, D. L. Lacey, D. Martin. (2006) Calcification Inhibitors and Wnt Signaling Proteins Are Implicated in Bovine Artery Smooth Muscle Cell Calcification in the Presence of Phosphate and Vitamin D Sterols. Calcified Tissue International 79:6, 431-442
CrossRef197
Angel LM de Francisco. (2006) Medical therapy of secondary hyperparathyroidism in chronic kidney disease: old and new drugs. Expert Opinion on Pharmacotherapy 7:16, 2215-2224
CrossRef198
Naibedya Chattopadhyay, Edward M. Brown. (2006) Role of calcium-sensing receptor in mineral ion metabolism and inherited disorders of calcium-sensing. Molecular Genetics and Metabolism 89:3, 189-202
CrossRef199
Giovanni FM Strippoli, Allison Tong, Suetonia C Palmer, Grahame J Elder, Jonathan C Craig, Giovanni FM Strippoli. 2006. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. .
CrossRef200
David M. SPIEGEL, Lynn CASEY, Susan BELL, Michelle PARKER, Michel CHONCHOL. (2006) Achieving targets for bone and mineral metabolism: The impact of cinacalcet HCl in clinical practice. Hemodialysis International 10:S2, S24-S27
CrossRef201
Akhtar Ashfaq, Michael Gitman, Pravin C Singhal. (2006) Emerging strategies for lowering serum phosphorous in patients with end-stage renal disease. Expert Opinion on Pharmacotherapy 7:14, 1897-1905
CrossRef202
I Bhan, A Shah, J Holmes, T Isakova, O Gutierrez, S-A Burnett, H Jüppner, M Wolf. (2006) Post-transplant hypophosphatemia: Tertiary ‘Hyper-Phosphatoninism’?. Kidney International 70:8, 1486-1494
CrossRef203
Nelson Kopyt. 2006. Chronic Kidney Disease. , 463-500.
CrossRef204
Jaume Almirall Daly, Maria Pau Valenzuela Mujica. (2006) The safety of phosphate binders. Expert Opinion on Drug Safety 5:5, 675-686
CrossRef205
Ilan Szwarc, ??ngel Argil??s, Val??rie Garrigue, Sylvie Delmas, Guillaume Chong, S??bastien Deleuze, Georges Mourad. (2006) Cinacalcet Chloride Is Efficient and Safe in Renal Transplant Recipients with Posttransplant Hyperparathyroidism. Transplantation 82:5, 675-680
CrossRef206
Eugene Daphnis, Kostas Stylianou, Irene Katsipi, Spyros Stratigis, Eva Karamitopoulou, Nikolaos Karkavitsas, John Kyriazis. (2006) Parathyromatosis and the Challenge of Treatment. American Journal of Kidney Diseases 48:3, 502-505
CrossRef207
Hiroaki Ogata, Fumihiko Koiwa, Hidetoshi Ito, Eriko Kinugasa. (2006) Therapeutic Strategies for Secondary Hyperparathyroidism in Dialysis Patients. Therapeutic Apheresis and Dialysis 10:4, 355-363
CrossRef208
K Kalantar-Zadeh, N Kuwae, D L Regidor, C P Kovesdy, R D Kilpatrick, C S Shinaberger, C J McAllister, M J Budoff, I B Salusky, J D Kopple. (2006) Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney International 70:4, 771-780
CrossRef209
H. J. L. M. TIMMERS, M. KARPERIEN, N. A. T. HAMDY, H. DE BOER, A. R. M. M. HERMUS. (2006) Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor. Journal of Internal Medicine 260:2, 177-182
CrossRef210
David A Bushinsky, Kevin K Frick, Keith Nehrke. (2006) Genetic hypercalciuric stone-forming rats. Current Opinion in Nephrology and Hypertension 15:4, 403-418
CrossRef211
Dharmarajan Ramaswamy, Petros Efthimiou, Isaiarasi Gnanasekharan, Anita Soni. (2006) Management of musculoskeletal complications in endstage renal disease: an update. Clinical Rheumatology 25:4, 440-442
CrossRef212
Braden Manns, William F. Owen, Wolfgang C. Winkelmayer, P.J. Devereaux, Marcello Tonelli. (2006) Surrogate Markers in Clinical Studies: Problems Solved or Created?. American Journal of Kidney Diseases 48:1, 159-166
CrossRef213
E Lewin, K Olgaard. (2006) Influence of parathyroid mass on the regulation of PTH secretion. Kidney International 70, S16-S21
CrossRef214
P TORRES. (2006) Cinacalcet HCl: A Novel Treatment for Secondary Hyperparathyroidism Caused by Chronic Kidney Disease. Journal of Renal Nutrition 16:3, 253-258
CrossRef215
Takehisa Kawata, Yasuo Imanishi, Keisuke Kobayashi, Naoyoshi Onoda, Senji Okuno, Yoshiaki Takemoto, Takeshi Komo, Hideki Tahara, Michihito Wada, Nobuo Nagano, Eiji Ishimura, Takami Miki, Tetsuro Ishikawa, Masaaki Inaba, Yoshiki Nishizawa. (2006) Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels. Journal of Bone and Mineral Metabolism 24:4, 300-306
CrossRef216
Joachim H Ix, L Darryl Quarles, Glenn M Chertow. (2006) Guidelines for disorders of mineral metabolism and secondary hyperparathyroidism should not yet be modified. Nature Clinical Practice Nephrology 2:6, 337-339
CrossRef217
Irina Shahapuni, Matthieu Monge, Roxana Oprisiu, Hakim Mazouz, Pierre-François Westeel, Philippe Morinière, Ziad Massy, Gabriel Choukroun, Albert Fournier. (2006) Drug Insight: renal indications of calcimimetics. Nature Clinical Practice Nephrology 2:6, 316-325
CrossRef218
Matthieu Monge, Irina Shahapuni, Roxana Oprisiu, Najeh El Esper, Philippe Morinière, Ziad Massy, Gabriel Choukroun, Albert Fournier. (2006) Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients. Nature Clinical Practice Nephrology 2:6, 326-336
CrossRef219
Chun-Tung Yeh, Yao-Ping Lin, Wu-Chang Yang, An-Han Yang, Ming-Yu Lai, Chih-Ching Lin. (2006) Rapid Recurrence of Hyperparathyroidism from Both Nodularly Hyperplastic Autograft at Forearm and Residual Tissues at Neck after Parathyroidectomy in a Hemodialysis Patient with Calciphylaxis. The American Journal of the Medical Sciences 331:5, 284-287
CrossRef220
Ewa Lewin, Jinxing Huan, Klaus Olgaard. (2006) Basic Science and Dialysis: Parathyroid Growth and Suppression in Renal Failure. Seminars in Dialysis 19:3, 238-245
CrossRef221
Giovanni F.M. Strippoli, Suetonia Palmer, Allison Tong, Grahame Elder, Piergiorgio Messa, Jonathan C. Craig. (2006) Meta-Analysis of Biochemical and Patient-Level Effects of Calcimimetic Therapy. American Journal of Kidney Diseases 47:5, 715-726
CrossRef222
Masafumi Fukagawa. (2006) Does cinacalcet safely and effectively maintain long-term PTH control in secondary hyperparathyroidism?. Nature Clinical Practice Nephrology 2:5, 248-249
CrossRef223
D A Bushinsky, K LaPlante, J R Asplin. (2006) Effect of cinacalcet on urine calcium excretion and supersaturation in genetic hypercalciuric stone-forming rats. Kidney International 69:9, 1586-1592
CrossRef224
Grahame Elder. (2006) Use of calcimimetic drugs. Nephrology 11, S240-S244
CrossRef225
P TORRES, D PRIE, L BECK, G FRIEDLANDER. (2006) New Therapies for Uremic Secondary Hyperparathyroidism. Journal of Renal Nutrition 16:2, 87-99
CrossRef226
A. Duval, O. Moranne, P. Vanhille, E. Hachulla, E. Delaporte. (2006) Artériolopathie calcique (Calciphylaxie). La Revue de Médecine Interne 27:3, 184-195
CrossRef227
Tadao Akizawa. (2006) Does sevelamer have greater skeletal benefit than calcium carbonate in children with secondary hyperparathyroidism?. Nature Clinical Practice Nephrology 2:3, 130-131
CrossRef228
Roy C. Ziegelstein, Yali Xiong, Chaoxia He, Qinghua Hu. (2006) Expression of a functional extracellular calcium-sensing receptor in human aortic endothelial cells. Biochemical and Biophysical Research Communications 342:1, 153-163
CrossRef229
Francesco Locatelli, Giuseppe Pontoriero, Monica Limardo, Flavia Tentori. (2006) Cinacalcet hydrochloride: calcimimetic for the treatment of hyperparathyroidism. Expert Review of Endocrinology & Metabolism 1:2, 167-179
CrossRef230
Nobuo Nagano. (2006) Pharmacological and clinical properties of calcimimetics: Calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacology & Therapeutics 109:3, 339-365
CrossRef231
Mariano Rodriguez, Sagrario Cañadillas, Ignacio Lopez, Escolástico Aguilera-Tejero, Yolanda Almaden. (2006) Regulation of parathyroid function in chronic renal failure. Journal of Bone and Mineral Metabolism 24:2, 164-168
CrossRef232
Steven C. Hebert. (2006) Therapeutic Use of Calcimimetics. Annual Review of Medicine 57:1, 349-364
CrossRef233
G. Klaus, A. Watson, A. Edefonti, M. Fischbach, K. Rönnholm, F. Schaefer, E. Simkova, C. J. Stefanidis, V. Strazdins, J. Walle, C. Schröder, A. Zurowska, M. Ekim. (2006) Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatric Nephrology 21:2, 151-159
CrossRef234
Joseph Vassalotti. 2006. Nutritional Strategies for the Patient with Diabetic Nephropathy. , 149-170.
CrossRef235
Yoshihiro Tominaga. (2006) Surgical Treatment of Secondary Hyperparathyroidism due to Chronic Kidney Disease. Upsala Journal of Medical Sciences 111:3, 277-292
CrossRef236
D L Andress. (2006) Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation. Kidney International 69:1, 33-43
CrossRef237
Stephane ROUEFF, Martine SAINT GEORGES, Van Thoai CHUONG, Abdelhamid ABBASSI, Catherine GUEDON, Marie C. VERNEJOUL, Pablo UREnA TORRES. (2006) Looking at calcimimetics impact on hypercalcemia of immobilization: Hypotheses and a case study. Hemodialysis International 10:1, 29-34
CrossRef238
Patricia A. Schenck, Dennis J. Chew, Larry Allen Nagode, Thomas J. Rosol. 2006. Disorders of Calcium: Hypercalcemia and Hypocalcemia. , 122-194.
CrossRef239
Peter Vestergaard. (2006) Current Pharmacological Options for the Management of Primary Hyperparathyroidism. Drugs 66:17, 2189-2211
CrossRef240
Patricia A. Schenck, Dennis J. Chew, Ellen N. Behrend. 2006. Update on Hypercalcemic Disorders. , 157-168.
CrossRef241
Betty J. Dong. (2005) Cinacalcet: An oral calcimimetic agent for the managementof hyperparathyroidism. Clinical Therapeutics 27:11, 1725-1751
CrossRef242
GRAHAME J ELDER. (2005) Parathyroidectomy in the calcimimetic era. Nephrology 10:5, 511-515
CrossRef243
HASSANE IZZEDINE, VINCENT LAUNAY-VACHER, SVETLANA KARIE, GILBERT DERAY. (2005) Immunosuppressive and calcimimetic drug-drug interactions. Kidney International 68:4, 1903-1904
CrossRef244
JOHN CUNNINGHAM, MARK DANESE, KURT OLSON, PRESTON KLASSEN, GLENN M CHERTOW. (2005) Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney International 68:4, 1793-1800
CrossRef245
Armin Zittermann, Stefanie S. Schleithoff, Reiner Koerfer. (2005) Putting cardiovascular disease and vitamin D insufficiency into perspective. British Journal of Nutrition 94:04, 483
CrossRef246
H. Reichel. (2005) Current treatment options in secondary renal hyperparathyroidism. Nephrology Dialysis Transplantation 21:1, 23-28
CrossRef247
Kevin J. Martin, Harald Juppner, Donald J. Sherrard, William G. Goodman, Mark R. Kaplan, George Nassar, Patricia Campbell, Mario Curzi, Chaim Charytan, Laura C. McCary, Matthew D. Guo, Stewart A. Turner, David A. Bushinsky. (2005) First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney International 68:3, 1236-1243
CrossRef248
Jeff C. Huffman, Gregory L. Fricchione. (2005) Hypercalcemic delirium associated with hyperparathyroidism and a vitamin D analog. General Hospital Psychiatry 27:5, 374-376
CrossRef249
John Cunningham. (2005) Management of Secondary Hyperparathyroidism. Therapeutic Apheresis and Dialysis 9:s1, S35-S40
CrossRef250
S. M. Moe. (2005) Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrology Dialysis Transplantation 20:10, 2186-2193
CrossRef251
Chaim Charytan, Jack W. Coburn, Michel Chonchol, James Herman, Y. Howard Lien, Wei Liu, Preston S. Klassen, Laura C. McCary, Vincent Pichette. (2005) Cinacalcet Hydrochloride Is an Effective Treatment for Secondary Hyperparathyroidism in Patients With CKD Not Receiving Dialysis. American Journal of Kidney Diseases 46:1, 58-67
CrossRef252
Dennis L. Andress. (2005) VITAMIN D IN HEALTH AND DISEASE: Vitamin D Treatment in Chronic Kidney Disease. Seminars in Dialysis 18:4, 315-321
CrossRef253
Joel D. Hernandez, Katherine Wesseling, Isidro B. Salusky. (2005) VITAMIN D IN HEALTH AND DISEASE: Role of Parathyroid Hormone and Therapy with Active Vitamin D Sterols in Renal Osteodystrophy. Seminars in Dialysis 18:4, 290-295
CrossRef254
Myles Wolf, Ravi Thadhani. (2005) VITAMIN D IN HEALTH AND DISEASE: Beyond Minerals and Parathyroid Hormone: Role of Active Vitamin D in End-Stage Renal Disease. Seminars in Dialysis 18:4, 302-306
CrossRef255
Catherine M Shanahan. (2005) Vascular calcification. Current Opinion in Nephrology and Hypertension 14:4, 361-367
CrossRef256
William G Goodman. (2005) Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease?. Current Opinion in Nephrology and Hypertension 14:4, 355-360
CrossRef257
Simon J Steddon, John Cunningham. (2005) Calcimimetics and calcilytics—fooling the calcium receptor. The Lancet 365:9478, 2237-2239
CrossRef258
Eli A. Friedman. (2005) Consequences and management of hyperphosphatemia in patients with renal insufficiency. Kidney International 67:s95, s1-s7
CrossRef259
A. E. Kruse. (2005) The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrology Dialysis Transplantation 20:7, 1311-1314
CrossRef260
A. L. Serra. (2005) Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrology Dialysis Transplantation 20:7, 1315-1319
CrossRef261
C. Henley. (2005) 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar(R)/Mimpara(R)) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrology Dialysis Transplantation 20:7, 1370-1377
CrossRef262
(2005) Reply from the Author. Kidney International 67:5, 2065-2066
CrossRef263
Panagiotis T. Vlagopoulos, Mark J. Sarnak. (2005) Traditional and Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease. Medical Clinics of North America 89:3, 587-611
CrossRef264
Cecelia A. Byrnes, Brian M. Shepler. (2005) Cinacalcet: A New Treatment for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. Pharmacotherapy 25:5, 709-716
CrossRef265
Irina Shahapuni, Janet Mansour, Laïd Harbouche, Bechir Maouad, Mohamed Benyahia, Khelifa Rahmouni, Roxana Oprisiu, Jean-François Bonne, Matthieu Monge, Najeh El Esper, Claire Presne, Philippe Moriniere, Gabriel Choukroun, Albert Fournier. (2005) Viewpoint: How Do Calcimimetics Fit Into the Management of Parathyroid Hormone, Calcium, and Phosphate Disturbances in Dialysis Patients?. Seminars in Dialysis 18:3, 226-238
CrossRef266
Esther A. González, Ziyad Al-Aly, Kevin J. Martin. (2005) Difficulties in Achieving the K/DOQI Practice Guidelines for Bone and Mineral Metabolism. Seminars in Dialysis 18:3, 171-174
CrossRef267
Malik Touam, Victorio Menoyo, David Attaf, Henri-Emile Thebaud, Tilman B. Drueke. (2005) High dialysate calcium may improve the efficacy of calcimimetic treatment in hemodialysis patients with severe secondary hyperparathyroidism. Kidney International 67:5, 2065-2065
CrossRef268
N. Kimata. (2005) Mineral metabolism and haemoglobin concentration among haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrology Dialysis Transplantation 20:5, 927-935
CrossRef269
J. Falger, T. M
ller. (2005) Die Nebenschilddr
CrossRef270
Markus Ketteler, Marie-Luise Gross, Eberhard Ritz. (2005) Calcification and cardiovascular problems in renal failure. Kidney International 67:s94, s120-s127
CrossRef271
Y.-H. H. Lien. (2005) Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrology Dialysis Transplantation 20:6, 1232-1237
CrossRef272
Paul D. Miller. (2005) Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Current Osteoporosis Reports 3:1, 5-12
CrossRef273
Angel LM de Francisco. (2005) Cinacalcet HCl: a novel therapeutic for hyperparathyroidism. Expert Opinion on Pharmacotherapy 6:3, 441-452
CrossRef274
Tilman B. Dr
CrossRef275
Matthew Colloton, Edward Shatzen, Gerald Miller, Catherine Stehman-Breen, Michihito Wada, David Lacey, David Martin. (2005) Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney International 67:2, 467-476
CrossRef276
Sharon M. Moe, Glenn M. Chertow, Jack W. Coburn, L. Darryl Quarles, William G. Goodman, Geoffrey A. Block, Tilman B. Drueke, John Cunningham, Donald J. Sherrard, Laura C. McCary, Kurt A. Olson, Stewart A. Turner, Kevin J. Martin. (2005) Achieving NKF-K/DOQItm bone metabolism and disease treatment goals with cinacalcet HCl. Kidney International 67:2, 760-771
CrossRef277
Carla Wood, Esther A Gonzalez, Kevin J Martin. (2005) Challenges in the Therapy of Secondary Hyperparathyroidism. Therapeutic Apheresis and Dialysis 9:1, 4-8
CrossRef278
Eberhard Ritz. (2005) Calcimimetics?fooling the calcium receptor. Pediatric Nephrology 20:1, 15-18
CrossRef279
Desmond Padhi, Robert Z Harris, Margaret Salfi, John T Sullivan. (2005) No Effect of Renal Function or Dialysis on Pharmacokinetics of Cinacalcet (Sensipar??/Mimpara??). Clinical Pharmacokinetics 44:5, 509-516
CrossRef280
Nobuo Nagano, Edward F. Nemeth. (2005) Functional Proteins Involved in Regulation of Intracellular Ca2+ for Drug Development: The Extracellular Calcium Receptor and an Innovative Medical Approach to Control Secondary Hyperparathyroidism by Calcimimetics. Journal of Pharmacological Sciences 97:3, 355-360
CrossRef281
Simon J. Steddon, Stanley L.S. Fan, John Cunningham. (2005) New Prospects for the Management of Renal Bone Disease. Nephron Clinical Practice 99:1, c1-c7
CrossRef282
Philip J. Klemmer. (2005) Calcium Loading, Calcium Accumulation, and Associated Cardiovascular Risks in Dialysis Patients. Blood Purification 23:1, 12-19
CrossRef283
Julia A Barman Balfour, Lesley J Scott. (2005) Cinacalcet Hydrochloride. Drugs 65:2, 271-281
CrossRef284
Angel L.M. de Francisco. (2004) Secondary hyperparathyroidism: Review of the disease and its treatment. Clinical Therapeutics 26:12, 1976-1993
CrossRef285
Robert Z. Harris, Desmond Padhi, Thomas C. Marbury, Robert J. Noveck, Margaret Salfi, John T. Sullivan. (2004) Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. American Journal of Kidney Diseases 44:6, 1070-1076
CrossRef286
ZAHID H BAJWA, KHURAM A SIAL, ATIF B MALIK, THEODORE I STEINMAN. (2004) Pain patterns in patients with polycystic kidney disease. Kidney International 66:4, 1561-1569
CrossRef287
MICHAEL P JONES, LLOYD IBELS, BRAD SCHENKEL, MARTIN ZAGARI. (2004) Reply from the Authors. Kidney International 66:4, 1712-1713
CrossRef288
Lynda Anne Szczech. (2004) The impact of calcimimetic agents on the use of different classes of phosphate binders: Results of recent clinical trials. Kidney International 66:s90, S46-S48
CrossRef289
Richard A. Sherman. (2004) Briefly Noted. Seminars in Dialysis 17:5, 423-424
CrossRef290
Willem Soudijn, Ineke van Wijngaarden, Ad P. IJzerman. (2004) Allosteric modulation of G protein-coupled receptors: perspectives and recent developments. Drug Discovery Today 9:17, 752-758
CrossRef291
Jaime Uribarri. (2004) K/DOQI Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease Patients: Some Therapeutic Implications. Seminars in Dialysis 17:5, 349-350
CrossRef292
Stewart, Andrew F., . (2004) Translational Implications of the Parathyroid Calcium Receptor. New England Journal of Medicine 351:4, 324-326
Full Text293
(2004) Cinacalcet for Secondary Hyperparathyroidism in Hemodialysis Recipients. New England Journal of Medicine 351:2, 188-189
Full Text294
Fitsum Guebre-Egziabher, Firas Easy, Laurent Juillard, Pierre-Jean Valette, Denis Fouque. (2004) Percutaneous ethanol injection treatment of severe hyperparathyroidism in maintenance dialysis: Risks and benefits. Hemodialysis International 8:3, 214-218
CrossRef295
E. Seeman. (2004) Clinical and Basic Research Papers - March and April 2004 Selections. International Bone and Mineral Society Knowledge Environment 1:6, 1-5
CrossRef296
Curhan, Gary, . (2004) Fooling the Parathyroid Gland — Will There Be Health Benefits?. New England Journal of Medicine 350:15, 1565-1567
Full Text
- Letters
